WO2006090824A1 - Gel composition and method for producing same - Google Patents

Gel composition and method for producing same Download PDF

Info

Publication number
WO2006090824A1
WO2006090824A1 PCT/JP2006/303391 JP2006303391W WO2006090824A1 WO 2006090824 A1 WO2006090824 A1 WO 2006090824A1 JP 2006303391 W JP2006303391 W JP 2006303391W WO 2006090824 A1 WO2006090824 A1 WO 2006090824A1
Authority
WO
WIPO (PCT)
Prior art keywords
gel composition
polymer
acid
mass
acid anhydride
Prior art date
Application number
PCT/JP2006/303391
Other languages
French (fr)
Japanese (ja)
Inventor
Tomoya Nihei
Runa Unagami
Kazuhiko Matsuda
Yoshifumi Yamagata
Hajime Gotoh
Takeyuki Asanuma
Narumi Tagaki
Yasunori Sakamoto
Original Assignee
Lion Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lion Corporation filed Critical Lion Corporation
Publication of WO2006090824A1 publication Critical patent/WO2006090824A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/24Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/58Adhesives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/60Liquid-swellable gel-forming materials, e.g. super-absorbents

Definitions

  • the present invention relates to a gel composition that can be used as a base for medical patches, wound dressings, taping agents, etc., a patch obtained by spreading the gel composition on a support, and the gel composition It relates to manufacturing methods. More specifically, the present invention relates to a gel composition having high adhesiveness to the skin or mucous membrane and having an excellent gel forming ability.
  • the method of administering a drug by the transdermal and transmucosal absorption route is that the effective concentration of the active ingredient in the body fluid is maintained and can be expected to be sustained immediately, and the absorption of the active ingredient Increased interest in recent years due to easy adjustment of speed, low risk of side effects, and effective use of medicinal ingredients that are less affected by stomach acid, digestive enzymes, etc., and less affected by metabolism due to the first-pass effect of the liver. ing.
  • a poultice prepared by adding a water-soluble polymer such as sodium polyacrylate or carboxybule polymer to water, SIS, Tapes with a plasticizer and tackifier added to rubber, silicon and acrylic polymers such as polyisobutylene, plaster agents, oily bases such as liquid paraffin and petrolatum, water absorption such as gelatin and sodium carboxymethylcellulose Ointment bases containing functional polymers are known.
  • a water-soluble polymer such as sodium polyacrylate or carboxybule polymer
  • SIS Tapes with a plasticizer and tackifier added to rubber
  • silicon and acrylic polymers such as polyisobutylene
  • plaster agents oily bases such as liquid paraffin and petrolatum
  • water absorption such as gelatin and sodium carboxymethylcellulose Ointment bases containing functional polymers
  • a hydrophilic polymer such as polyacrylic acid and carboxymethyl cellulose and water, one selected from the group consisting of rosin ester, hydrogenated petroleum resin, and terpene-based resin Medical patch containing the above tackified rosin (see Patent Document 1) ),
  • a pressure-sensitive adhesive composition containing a polymer soluble in a lower alcohol and having a carboxyl group or a salt thereof, a lower alcohol, a polyhydric alcohol, and metal sulphate, and gelled see Patent Document 2
  • Adhesive gel base using methyl vinyl ether maleic anhydride copolymer or methyl vinyl ether maleic acid copolymer as the base polymer, polyfunctional epoxy compound as the cross-linking agent, and gelling water and polyhydric alcohol (Patent Literature) 3) has been proposed.
  • these bases contain water or lower alcohol having a relatively low boiling point as the main component, water or lower alcohol evaporates during use, resulting in performance such as stickiness and skin irritation
  • anhydrous gel matrix having a hydroxyl group and a Z or carboxyl group in the molecule using a cross-linking agent and gelling the polyhydric alcohol with a polyhydric alcohol-soluble polymer see Patent Document 4
  • a non-aqueous patch in which a polyhydric alcohol is gelled with a polyhydric alcohol-soluble polymer and a strong ropoxyvinyl polymer has also been proposed.
  • a non-aqueous thermal gel composition (see Patent Document 6) characterized by containing a polyhydric alcohol and a power that dissolves in the polyhydric alcohol or a polymer that swells with the polyhydric alcohol has also been proposed. ing. Since the main component of this base is a polyhydric alcohol, the essential components that hardly deteriorate with time are a polyhydric alcohol and a polymer, and it is expected that the manufacturing operation is simple. However, there are cases where the adhesiveness and gel-forming ability are insufficient, with no mention of adhesiveness and gel-forming ability.
  • Patent Document 1 Japanese Patent Laid-Open No. 6-254150
  • Patent Document 2 Japanese Patent Laid-Open No. 9-143062
  • Patent Document 3 Japanese Patent Laid-Open No. 9-286891
  • Patent Document 4 Japanese Patent Laid-Open No. 63-203162
  • Patent Document 5 Japanese Patent Laid-Open No. 2003-113077
  • Patent Document 6 Japanese Patent Laid-Open No. 2001-245913 Disclosure of the invention
  • the present invention provides a gel composition having high adhesion to skin or mucous membrane and having an excellent gel-forming ability, a patch using the gel composition, and a method for producing the gel composition.
  • the purpose is to do.
  • the present inventors have found that a polymer and a polyhydric alcohol in which the acid anhydride portion and the corresponding acid compound portion in the polymer are in a specific range.
  • the inventors have found that a gel composition having high adhesion to the skin or mucous membrane and having an excellent gel forming ability can be obtained, and the present invention has been completed.
  • the present invention comprises (A) a repeating unit composed of at least one unsaturated portion and an acid anhydride portion, and at least one unsaturated portion and an acid compound portion corresponding to the acid anhydride portion.
  • a gel composition comprising a polymer containing a repeating unit, and (B) a polyhydric alcohol,
  • the gel composition is characterized in that the polymer contains an acid anhydride portion and an acid compound portion corresponding to the acid anhydride portion in a molar ratio of 15Z85 to 85Z15.
  • the present invention also provides a patch in which the gel composition is spread on a support.
  • the present invention also includes (a) hydrolyzing a polymer containing a repeating unit composed of at least one unsaturated portion and an acid anhydride portion, and an acid anhydride portion contained in the polymer.
  • a repeating unit composed of at least one unsaturated portion and an acid anhydride portion wherein the acid compound portion corresponding to the acid anhydride portion is a molar ratio of 15Z85 to 85Z15, Obtaining a polymer comprising a repeating unit composed of at least one unsaturated moiety and an acid / acid compound moiety corresponding to the acid anhydride moiety,
  • a method for producing a gel composition is provided.
  • the invention's effect is provided.
  • the present invention it is possible to provide a gel composition having high adhesion to the skin or mucous membrane and having an excellent gel forming ability. According to the present invention, it is also possible to provide a gel composition that hardly causes skin irritation with a small deterioration power S of performance.
  • an external preparation composition such as a patch excellent in transdermal absorbability of a medicinal component, preferably excellent in initial transdermal absorbability.
  • the gel composition of the present invention is excellent in solubility of medicinal components, particularly medicinal components that are difficult to absorb percutaneously, and can provide an external preparation composition with an increased amount of medicinal components.
  • the gel composition of the present invention also has good usability and can be applied to various preparations.
  • the polymer (A) used in the present invention has a mono ktt force of 15/85 to 85/15, preferably 15/85 of an acid anhydride portion and an acid compound portion corresponding to the acid anhydride portion. -80/20, more preferably 20Z80-70Z30. Within such a range, it is preferable because it has both high adhesiveness and excellent gel forming ability. If the ratio of the acid anhydride is too high, it becomes difficult to obtain a gel composition having both high tackiness and excellent gel-forming ability. If the ratio of the acid compound portion is too high, the gel composition has excellent gel-forming ability. It becomes difficult to obtain a gel composition.
  • the molar ratio between the acid anhydride and the acid compound portion corresponding to the acid anhydride portion can be measured by potentiometric titration.
  • the polymer has the same number of moles of at least one unsaturated portion as the sum of the number of moles of the acid anhydride portion and the number of moles of the acid compound portion corresponding to the acid anhydride portion. I like it.
  • the weight average molecular weight of the (ii) polymer of the present invention is preferably high enough to obtain good gel-forming ability, for example, 10,000 to 10,000,000, preferably 100,000 to 5,000,000. This average molecular weight is a value measured by a size exclusion separation low angle laser light scattering detector method.
  • the blending amount of the polymer with respect to the gel composition of the present invention is, for example, 1 to 55 quality. The amount is preferably 1 to 40% by mass, more preferably 1 to 30% by mass.
  • At least one unsaturated portion is a beluie compound.
  • the vinyl compound include methyl vinyl ether, styrene, ethylene, isobutylene and the like. Of these, methyl beryl ether is preferred.
  • the acid anhydride portion is preferably selected from the group strength of maleic anhydride portion and itaconic anhydride partial force. More preferably, (A) the polymer is an alkyl butyl ether having 3 to 24 carbon atoms, a maleic anhydride, a maleic anhydride, a maleic acid copolymer, an alkyl bulle ether having 3 to 24 carbon atoms, and itaconic anhydride. Z-taconic acid power Constructed copolymer power is selected. More preferred are a copolymer composed of methyl vinyl ether Z maleic anhydride Z maleic acid and a copolymer composed of methyl vinyl ether Z itaconic anhydride Z itaconic acid. Of these, a copolymer composed of methyl vinyl ether Z maleic anhydride and maleic acid is most preferred.
  • the (A) polymer of the present invention includes, for example, a monomer containing at least one unsaturated moiety, a monomer containing an acid anhydride moiety, and a monomer containing an acid compound moiety corresponding to the acid anhydride moiety. It can also be produced by copolymerization or (a) by hydrolysis of a polymer containing a repeating unit composed of at least one unsaturated moiety and an acid anhydride moiety.
  • a) polymer for example, those commercially available from ISP as GA NTREZ AN series can be used.
  • Hydrolysis is performed, for example, on (a) 100 parts by mass of polymer, 2 to: LOO parts by mass, preferably 2 to 50 parts by mass of water, and at a temperature of 20 to 100 ° C. for 1 to 600 minutes, This can be done by reacting.
  • the polymer may be dissolved in a solvent such as acetone, tetrahydrofuran, dimethyl sulfoxide, dimethylformamide in advance, and water may be added thereto, or water may be sprayed onto the polymer.
  • the polymer may be absorbed as water vapor.
  • the gel composition of the present invention is formulated into a patch or the like, it is possible to reduce the degree to which the adhesiveness or the like decreases with time during use.
  • the obtained polymer can be used as it is, or it can be used after removing water present in the system to about 1% with respect to the polymer by heating, drying under reduced pressure or the like.
  • the polyhydric alcohol used in the present invention preferably does not evaporate during use.
  • Glycerin, triglycerin, polyglycerin, polyethylene glycol, dipropylene glycol, triethylene glycol, polyethylene glycol monourea (weight average molecular weight 200-2000, preferably 200-600), positive P-pilling !; 3— (weight Average molecular weight 400-4000, preferably 400-1000), polyethylene 'polypropylene monole (weight average molecular weight 1000-6000, preferably ⁇ 1000-3000), positive aged hydrogenated castor oil (5E.O.-100E) O., preferably 10E. O. to 60E. O.) and sorbitol, etc., and these may be used alone or in combination of two or more. Can be used in appropriate combinations.
  • the weight average molecular weight is 200 to 2000, more preferably 200 to 1500, more preferably ⁇ is 200 to 1000, and particularly preferably ⁇ is 200 to 600.
  • polyethylene glycol it is particularly preferable to use a polyvalent alcohol other than polyethylene glycol because the transdermal absorbability of the medicinal component is improved.
  • polyhydric alcohols other than polyethylene glycol include dihydric alcohols such as ethylene glycol, propylene glycol, 1,3-butylene glycol, diethylene glycol and dipropylene glycol, and trivalent alcohols such as glycerin and trimethylolpropane.
  • dihydric alcohols such as ethylene glycol, propylene glycol, 1,3-butylene glycol, diethylene glycol and dipropylene glycol.
  • dihydric alcohols such as ethylene glycol, propylene glycol, 1,3-butylene glycol, diethylene glycol and dipropylene glycol.
  • it is preferably used as a dihydric or hexahydric polyhydric alcohol mixture containing polyethylene glycol having a weight average molecular weight of 200 to 2000! /.
  • the mixing ratio of polyethylene glycol and divalent to 6-valent polyhydric alcohols other than polyethylene glycol is 1: 9-: LO: 0 is preferred by mass ratio 1: 9-9: 1 is more preferred 2 : 8-8: 2 is more preferable.
  • LO: 0 is preferred by mass ratio 1: 9-9: 1 is more preferred 2 : 8-8: 2 is more preferable.
  • the measuring method of the weight average molecular weight of the polyhydric alcohol which is a polymer can be measured by a titration test described in the cosmetic raw material standards.
  • the blending amount of the polyhydric alcohol with respect to the gel composition of the present invention is, for example, 40 It is 50 mass%-99 mass%, Preferably, it is 50 mass%-99 mass%, More preferably, it is 60 mass%-99 mass%. Further, the total amount of the polymer (A) and the polyvalent alcohol in the gel composition of the present invention is, for example, 60% by mass or more, preferably 65% by mass or more, and more preferably 70% by mass or more. Hope U ,.
  • the mass ratio of the polymer (A) of the present invention to the polyhydric alcohol is 1Z99 to 55Z45, preferably 1Z99 to 45Z55, and more preferably 1Z99 to 35Z65.
  • the gel composition of the present invention may optionally contain a polymer that dissolves or swells in the polyhydric alcohol used.
  • dissolution means that a polyvalent alcohol solution of 1% by mass of a polymer becomes uniform.
  • Swelling refers to a state in which a polymer absorbs polyhydric alcohol and increases its volume when mixed with a certain mass of polyhydric alcohol, and the mass of this polyhydric alcohol mixture is the polymer before mixing. This is when the mass is twice or more.
  • the polymer is preferably gelled by dissolving or swelling in a polyhydric alcohol.
  • the gel composition of the present invention may optionally contain additives such as pressure-sensitive adhesives, binders, medicinal ingredients, transdermal absorption enhancers, other active ingredients, perfumes, and pigments. It is preferable to contain at least one selected from the group consisting of a pressure-sensitive adhesive, a binder, and a mixture thereof because the pressure-sensitive adhesiveness of the gel composition of the present invention can be improved. Further, when the gel composition of the present invention contains a medicinal component, it is preferable because the medicinal effect can be sustained. When the transdermal absorption enhancer is contained, the gel composition of the present invention contains a medicinal component. It is preferable because the percutaneous absorbability of the medicinal component, particularly the initial percutaneous absorbability, is improved.
  • the additive used in the present invention is not particularly limited as long as it can be dissolved or dispersed in a polyhydric alcohol.
  • active ingredients include warm sensation active ingredient, cool sensation active ingredient, terminal circulation promoting agent, anti-inflammatory analgesic ingredient, blood circulation promoter, local anesthetic agent, antiperspirant, athlete's foot drug, antibacterial / bactericidal ingredient, Antibacterial and sterilizing agents, whitening ingredients, sebum suppressants, keratolytic agents, active ingredients for cervical sprains, and astringent ingredients. These can be used alone or in combination of two or more.
  • Adhesives such as rosin ester, alicyclic resin, and polyterpene resin are mixed with elastomers such as styrene Z isoprene Z styrene block copolymer (SIS) and polyisobutylene (PIB).
  • Rubber adhesives acrylic adhesives such as polyacrylic acid, polyacrylate (preferably sodium salt), acrylic acid Z methacrylic acid copolymer; silicone adhesives such as polysiloxane derivatives; alkyl Examples include vinyl ether-based adhesives such as vinyl ether Z maleic anhydride copolymer; and butyl acetate-based adhesives such as acrylic ester Z vinyl acetate copolymer.
  • These pressure-sensitive adhesives may be used alone or in combination of two or more. Acrylic adhesives and vinyl ether adhesives are more preferably used.
  • the mass average molecular weight of the pressure-sensitive adhesive is preferably 10,000 to 10,000,000, more preferably 10,000 to 50,000,000!
  • the blending amount of the pressure-sensitive adhesive is preferably 1 to 78% by mass, more preferably 5 to 75% by mass in the composition. If it is at least the lower limit of the range, sufficient adhesion to the use site of the gel composition is obtained, and if it is at most the upper limit, the peelability of the use site force of the gel composition is good.
  • binder examples include carboxyvinyl polymer, alginic acid, polybutyl alcohol, polyvinyl pyrrolidone, carboxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose and the like. Among these, carboxyvinyl polymer and hydroxypropylcellulose are preferred, and hydroxypropylcellulose is more preferred.
  • the weight average molecular weight of the binder is preferably 10,000 to 100,000,000, more preferably 50,000 to 5,000,000.
  • the weight average molecular weight of the binder is
  • It can be measured by gel permeation chromatography method or light scattering method.
  • a value converted into polyethylene oxide by gel permeation chromatography method and in the case of hydroxypropyl cellulose, gel permeation.
  • gel permeation Use the value calculated by pullulan conversion by the Chillon chromatography method, or the value measured by the light scattering method in the case of polybulurpyrrolidone.
  • binders may be used alone or in combination of two or more.
  • the blending amount of the binder is preferably 1 to 30% by mass and more preferably 1 to 20% by mass in the composition. If it is this range, the retention property of the composition in the applied part will become favorable, and the sustainability of a medicinal effect can be improved.
  • the blending amount of the mixture is preferably 1 to 78% by mass, more preferably 5 to 75% by mass in the composition.
  • the medicinal properties include non-steroidal anti-inflammatory drugs such as indomethacin, fuel binac, ketoprofen, flurbiprofen, diclofenac, and ester derivatives thereof; antihistamines such as diphenhydramine, central nervous system drugs such as isoprenaline hydrochloride, estradiol and testosterone Hormonal agents; analgesics such as aspirin, acetaminophen, ibuprofen; antiarrhythmic agents such as disopyramide phosphate; coronary vasodilators such as tolazoline hydrochloride; local anesthetics such as lidocaine; muscle relaxants such as skisamethonium chloride; Antifungal agents such as clotrimazole, anti-neoplastic agents such as fluorouracil, dysuria such as tamsulosin hydrochloride, antiepileptic agents such as diazepam, antiparkinsonian agents such as bromocriptine me
  • the active ingredients for warm feeling include, for example, red pepper extract, red pepper tincture, kabusaicin, Twilight extract, meat katsura, ginger extract, ginger alcohol extract, cantalis tincture
  • Nicotinic acid benzyl ester vitamin E, borneol, dl-camphor, 1-menthol, heart force oil, eucalyptus oil, methyl salicylate, glycol salicylate, ⁇ ⁇ -allyl alcohol derivatives, ⁇ -rilamide of norlate, vanillyl
  • Examples include alcohol alkyl ethers, pepper family plant extracts, sage genus plant extracts, argentia genus plant extracts, clove oil, and eugenol derivatives. When these components are added, blood circulation can be promoted using a local or induced stimulus to the skin, and a warm feeling can be obtained.
  • Active ingredients for cooling sensation include, for example, menthol, menthol glycerol ether, and derivatives of these compounds such as esters, N-ethyl-p-3-menthane-carboxamide, heart force oil, and force flu.
  • menthol menthol glycerol ether
  • derivatives of these compounds such as esters, N-ethyl-p-3-menthane-carboxamide, heart force oil, and force flu.
  • the peripheral circulation promoting agent includes, for example, tocolol acetate.
  • Anti-inflammatory analgesic components include, for example, salicylic acid, methyl salicylate, glycol salicylate, diphenhydramine, chlorfelamamine maleate, ammonium glycyrrhizinate, dicalium glycyrrhizinate, glycyrrhizic acid, stearyl glycyrrhizinate, 13-darlicylretinoic acid, , Azulene, ⁇ -aminocaproic acid, hydrocortisone, calcium pantothenate, ethyl pantothenate, hydrocortisone acetate, nor-hydroxamide, diphenol hydramine, indomethacin, ketoprofen, flurbiprofen, ibuprofen, suprofen, Loxoprofen, Zaltoprofen, Piroxicam, Fuerbinac, Arnica
  • Examples of the blood circulation promoter include senpri extract, cephalanthin, vitamin ⁇ and its derivatives, ⁇ oryzanol, peppermint oil, turpentine oil, thiodi oil, geraol oil, thymol oil, wikiyou oil, bergamot oil, anise Oil, Lavender oil, Black pepper oil, Beninona oil, Anole extract, Maronier extract, Enmeiso extract, Bodaige extract, Melissa extract, ⁇ ethyl ⁇ -3-menthane monocarboxamide, etc.
  • Examples of local anesthetics include funnel extract, jib force-in, pro force-in, and lidocaine.
  • Tannin-containing components are preferably used as the brick component.
  • An inorganic salt is preferably used as the perspiration promoter.
  • calcined gypsum calcium chloride, anhydrous calcium chloride, magnesium chloride, anhydrous magnesium chloride, calcium carbonate, anhydrous calcium carbonate, sodium sulfate, anhydrous sodium sulfate, magnesium sulfate, anhydrous magnesium sulfate, sodium hydroxide, potassium hydroxide
  • Sterilization ⁇ Antibacterial components include, for example, pyrotatone olamine, cyclopilotas olamine, benzalkonium chloride, benzethonium chloride, halocarban, clohexhexidine hydrochloride, zinc pyrithione, phenol, trichlorocarba -Lido, chlorhexidine dalconate, cetyl pyridinium chloride, isopropylmethylphenol, allantoin, anti-plasmin agent ( ⁇ -aminocaproic acid, tranexamic acid), dihydrocholesterol, tonic extract, force mitre (containing azulene), There are essential oils such as eucalyptus oil and hinokitiol.
  • quinuhada Callophyllis flabellulata
  • water extract which is an active ingredient, miconazole nitrate, and other antipruritic agents, diphenhydramine hydrochloride, chlorfelamine maleate, camphor, and labrite are used.
  • Antibacterial 'bactericidal agents include, for example, zinc pyrithione, trichlorocarbalide, triclosan, aloe extract, carrot extract, licorice extract, wolverine extract, force extract, birch extract, water-soluble cerium salt, abietic acid, pimaric acid, Sulfur containing bis (2-pyridinethiol 1 oxide) zinc, pyridinethione salt, histamine 2 receptor antagonist, vitamin E acetate, pantothruethyl ether, citrate triethyl ester, methionine, cystine, cysteine, etc.
  • a whitening component, a sebum inhibitor, a keratolytic agent, and the like can be used mainly when used as a cosmetic.
  • Whitening ingredients include, for example, arbutin, ellagic acid, kojic acid, hydroquinone, vitamin C, placenta extract, titanium oxide, water extract of Callophyllis japonica, and water extract of Callophyllis adhaerens. There is.
  • sebum inhibitors and keratolytic agents examples include estradiol, estrone, ethynylestradiol, vitamin B6, io, resorcin, benzalkonium chloride, benzethonium chloride, halocarban, 2, 4, 4 —Trichrome mouthpieces 2-hydroxyphenol, selenium sulfide, pentadecanoic acid, pentadecanoic acid derivatives, various vitamins, etc.
  • non-steroid anti-inflammatory agents such as indomethacin, fuerbinac, ketoprofen, flurbiprofen, diclofenac and the like, which are preferably poorly water-soluble medicinal ingredients because the effects of the present invention are particularly remarkable; estradiol, testosterone, etc.
  • Hormonal agents, antihypertensive agents such as furosemide and clonidine, vasodilators such as nitroglycerin and isosorbide nitrate, smoking cessation aids such as nicotine, bronchodilators such as lolobtail, scopolamine and fentanyl are more preferred. More preferred are indomethacin, fuel binac, ketoprofen and flurbiprofen.
  • These medicinal ingredients may be used alone or in combination of two or more.
  • “poorly water-soluble medicinal ingredient” is an index of sparingly soluble, for example, when it shows solubility in water according to the Japanese pharmacy property test, “very insoluble!” Or “almost insoluble! /, "The medicinal ingredient for which the term” is used.
  • the compounding amount of the medicinal component in the gel composition of the present invention can be appropriately set by those skilled in the art, and is preferably about 0.05 to 70% by mass in the composition.
  • R 1 is a hydrocarbon group having 3 to 36 carbon atoms
  • R 2 is a hydrocarbon group having 1 to 20 carbon atoms
  • R 3 is a hydrogen atom or —COOR 4 and R 4 is 1 carbon atom.
  • It is a hydrocarbon group of L0.
  • the ester represented by these is mention
  • R 1 represents a hydrocarbon group having 3 to 36 carbon atoms, preferably 4 to 20 carbon atoms, which may be linear, branched or saturated or unsaturated. Good. A carbon number in this range is preferable because it is excellent in transdermal absorbability of medicinal ingredients and solubility in polyhydric alcohols including polyethylene glycol.
  • R 3 is a hydrogen atom
  • the number of carbon atoms is preferably 10 to 36.
  • COOR 4 is selected, the number of carbon atoms is preferably 3 to 20.
  • R 2 represents a hydrocarbon group having 1 to 20 carbon atoms, preferably 1 to 18 carbon atoms, which may be linear, branched or saturated or unsaturated. Good.
  • R 3 is a hydrogen atom, the number of carbon atoms is preferably 1-18.
  • R 3 is one COOR 4, the number of carbon atoms is preferably from it preferably instrument is 1-10 1-6, more preferably 1-3.
  • R 3 represents a hydrogen atom or COOR 4 and R 4 represents a hydrocarbon group having 1 to 10 carbon atoms, preferably 1 to 8 carbon atoms, and the hydrocarbon group may be linear or branched. It may be saturated or unsaturated.
  • R 2 and R 4 may be the same as or different from each other.
  • transdermal absorption enhancer examples include decyl sebacate, diisopropyl sebacate, decyl adipate, diisopropyl adipate, oleyl oleate, isopropyl myristate, isopropyl palmitate, ethyl linoleate, isopropyl linoleate. And the like. Of these, decyl sebacate, diisopropyl sebacate, diisopropyl adipate, oleyl oleate, and isopropyl myristate are preferred. Especially preferred is Jetyl Sebacate! /.
  • transdermal absorption enhancers may be used alone or in combination of two or more.
  • the blending amount of the transdermal absorption enhancer is preferably 1 to 50% by weight in the composition, 3 to 40% by weight, more preferably 5 to 30% by weight, and even more preferably 10 to 30% by weight. preferable. Within such a range, the transdermal absorbability of the medicinal component is good.
  • the mixing ratio of the polyhydric alcohol and the transdermal absorption enhancer is preferably 1: 9 to 9: 1 in terms of mass ratio, more preferably 2: 8 to 8: 2. Within this range, both the solubility of the medicinal component and the transdermal absorbability of the medicinal component are excellent.
  • transdermal absorption enhancer examples include crotamiton and benzyl alcohol, and these can be used singly or in appropriate combination of two or more.
  • fragrances include amylcinnamic aldehyde, benzyl acetate, p-tert butynolecyclohexenole acetate, cyclaset, cyclaprop, garaki solid, bedeon, orange oil and the like.
  • the dye is not particularly limited, and the dyes described in the Legal Dye Handbook can be blended. For example, Red 2, Green 3, Blue 1, Dai 402, Yellow 401, Purple 401, etc. is there.
  • the gel composition of the present invention can be produced by dissolving (A) a polymer in (B) a polyhydric alcohol, and performing a crosslinking reaction with the polyhydric alcohol to form a gel.
  • a crosslinking reaction with the polyhydric alcohol to form a gel.
  • the heating may be performed while kneading or kneading (A) the polymer and (B) the polyhydric alcohol.
  • the slurry containing (A) the polymer and (B) the polyhydric alcohol is made into a nonwoven fabric or the like.
  • the heating temperature is different depending on the (B) polyhydric alcohol used.
  • (B) In the range not exceeding the boiling point of the polyhydric alcohol, for example, about 20 ° C to 250 ° C, preferably 40 ° C to It is desirable that the temperature be about 200 ° C, more preferably about 60 ° C to 180 ° C.
  • the heating time is, for example, 10 minutes to 10 hours, preferably 30 minutes to 4 hours.
  • the gel composition of the present invention is not particularly limited in its use and dosage form.
  • it is used as an external preparation composition that can be applied to skin, hair, oral cavity (including mucous membranes), nails and the like.
  • the dosage form is not particularly limited, and includes patches (medical patches, wound dressings, tabing agents, foot care sheet agents, knock agents, mask agents), ointments, gels, and coating agents.
  • a patch is preferred.
  • the coating amount of the external preparation composition is preferably about 0.01 to about Lg / cm 2 , for example, depending on the types of medicinal ingredients and binders used.
  • the composition for external use can be produced by a conventional method.
  • the patch is obtained by spreading the gel composition on a support
  • the spreading method is not particularly limited, and can be performed using a known apparatus, for example, a roll coater.
  • a knife coater, a slit die coater, a gravure coater or the like can be used.
  • a support body a well-known thing can be used, For example, paper, a knitted fabric, a woven fabric, a nonwoven fabric, a polymer film, or those laminated bodies etc. can be mentioned.
  • Materials for knitted fabric, woven fabric, non-woven fabric, and polymer film include polyester, polypropylene, rayon, Examples include butyl chloride, polyethylene, polyurethane, and polyurethane 'vinyl chloride copolymer film.
  • the amount of spreading when the gel composition is spread on the support is not particularly limited, and it is 0.001 to 1 lg / cm 2 , preferably 0. 003 to 0.5 g / cm 2 , more preferably 0.005 to 0.2 gZcm 2 .
  • the patch of the present invention after spreading the gel composition, is used as needed for the purpose of preventing volatilization of medicinal ingredients, protecting the adhesive surface, etc.
  • a facing layer may be provided on the top and covered.
  • the facing layer is not particularly limited as long as it can protect the patch, and examples thereof include plastic films such as polypropylene film, polychlorinated bull film, polyethylene film, and polyethylene terephthalate film, and release paper.
  • the patch can then be cut into an appropriate size and used.
  • the cutting method may be any cutting method such as slitting, cutting by push-cutting, or a combination of these, or the punching cutting method.
  • the adhesive patch of the present invention has an adhesive strength adjusted to 4 to 32, preferably 6 to 30, when measured at an inclination angle of 30 °. Is preferred. If it is at least the lower limit of the range, sufficient adhesion to the site of use of the patch can be obtained, and if it is not more than the upper limit, the patch can be peeled off with little skin irritation.
  • the adhesive strength of the patch can be adjusted by selecting the adhesive and controlling the blending amount.
  • Examples 1A to: L 1A, 13A and 14A and Comparative Examples 1A to 4A are gel compositions obtained by kneading each component with a bench-kinder (PNV-1, manufactured by Hitachi, Ltd.) polyester - Tsu DOO such that 0. lgZcm 2 on (Toho Textile Co., Ltd.), and uniformly spread by a roll coater (manufactured by Hanae machinery industry Co.), and the sheet.
  • PNV-1 bench-kinder polyester - Tsu DOO
  • 0. lgZcm 2 on Toho Textile Co., Ltd.
  • a roll coater manufactured by Hanae machinery industry Co.
  • Example 12A is a polyester knit (manufactured by Toho Textile Co., Ltd.), in which each component was kneaded for 5 minutes at room temperature with a bench-top (PNV-1, manufactured by Hitachi, Ltd.). ) Up 0 It was prepared by heating after uniformly coating with a roll coater (manufactured by Kaei Machine Industry Co., Ltd.) so that lgZcm 2 was obtained. The gel forming ability of each gel composition and the adhesiveness of each patch were evaluated by the following methods.
  • the gel composition has a higher gel-forming ability as the storage elastic modulus has a lower frequency dependency. Therefore, the present inventors investigated how much the storage elastic modulus of the prepared gel composition is affected by the change of the measurement frequency, and evaluated the gel forming ability.
  • the storage elastic modulus was measured with a stress-controlled rheometer (Rheo—Stress RS—100, manufactured by Haake) at 25 ° C, and the storage elastic modulus (G ′ (0. 1)) with a frequency of 0. IradZsec.
  • the gel-forming ability was evaluated from the value of the ratio (G, (10) ZG ′ (0.1)) to the storage elastic modulus (G, (10)) of lOradZ sec.
  • G '(10) ZG' (0.1) is 0.67 or more and less than 1.5 ⁇ ⁇ '', 0.5 or more and less than 0.67, and 1.5 or more and less than 2 is ⁇ ⁇ '', Less than 0.5 and 2 or more were designated as “X”.
  • the produced sheet was evaluated with a texture analyzer (TA-XT2, manufactured by Stable Micro Systems).
  • a probe with a diameter of 20 mm covered with a collagen film was adhered to the sheet with a load of 100 g for 10 seconds, and then the peeling operation when peeling at a peeling speed of lOmmZsec was evaluated as tackiness.
  • the evaluation was “O” for lOOOg'mm or more, “ ⁇ ” for 500g′mm or more and less than 1000 8'111111, and “” for 50 ( ⁇ '111111 or less.
  • Methyl beryl ether Z Maleic anhydride Copolymer (ISP, GAN TREZ AN—139) 100 mass%, 8 mass% water added, 90 ° C [Koo!
  • a copolymer (molecular weight: 1.08 million) composed of methyl vinyl ether Z maleic anhydride Z maleic acid having a molar ratio of maleic anhydride Z maleic acid of 56Z44 was obtained as polymer (A). .
  • Methyl beryl ether Z Maleic anhydride Power copolymer (ISP, GAN TREZ AN—139) 100 mass% of water, 15 mass% of water added, and then hydrolyzed at 90 ° C for 300 minutes.
  • ISP Methyl beryl ether Z Maleic anhydride Power copolymer
  • GAN TREZ AN—139 Methyl beryl ether Z Maleic anhydride Power copolymer
  • Methyl beryl ether Z Maleic anhydride Copolymer (ISP, GAN TREZ AN—169) Add 100 parts by mass of 4 parts by mass of water and hydrolyze at 90 ° C for 180 minutes As a result, a copolymer (molecular weight: 1.98 million) composed of methyl vinyl ether Z maleic anhydride Z maleic acid having a maleic anhydride Z maleic acid molar ratio of 70Z30 was obtained as the polymer (A).
  • Methyl vinyl ether Z Maleic anhydride Copolymer (ISP, GAN TREZ AN—169) Add 100 parts by weight of 3 parts by weight of water and hydrolyze at 90 ° C for 180 minutes As a result, a copolymer (molecular weight: 1.98 million) composed of methyl vinyl ether Z maleic anhydride Z maleic acid having a molar ratio of maleic anhydride Z maleic acid of 74Z26 was obtained as the polymer (A).
  • Methyl vinyl ether Z Maleic anhydride Copolymer (ISP, GAN TREZ AN—169) 100 mass%, add 2 mass% of water, and add 90 ° C.
  • a copolymer (molecular weight 1.98 million) composed of methyl vinyl ether Z maleic anhydride Z maleic acid having a molar ratio of maleic anhydride Z maleic acid of 77Z23 was obtained as (A) polymer. . 20 parts by mass of the obtained (A) polymer and 80 parts by mass of polyethylene glycol (PEG400, manufactured by Lion Corporation) were kneaded at 90 ° C. for 90 minutes, and then spread into a sheet.
  • PEG400 polyethylene glycol
  • Methyl beryl ether Z Maleic anhydride Copolymer (ISP, GAN TREZ AN—169) 100 mass%, 2 mass% of water is added, and 90 o C
  • a copolymer (molecular weight: 1.98 million) composed of methyl vinyl ether Z maleic anhydride Z maleic acid having a molar ratio of maleic anhydride Z maleic acid of 84Z16 was obtained as (A) polymer. .
  • Methyl beryl ether Z Maleic anhydride Powered copolymer (ISP, GAN TREZ AN—139) 100 mass%, 20 mass% of water is added, and 90 ° C [Koo!
  • a copolymer (molecular weight 1.08 million) composed of methyl vinyl ether Z maleic anhydride Z maleic acid having a molar ratio of maleic anhydride to maleic anhydride of 17Z83 is obtained as the polymer (A). Obtained.
  • Methyl beryl ether Z Maleic anhydride Powered copolymer (ISP, GAN TREZ AN—119) 100 mass%, 25 mass% water added, 20 ° C [Koo!
  • a copolymer (molecular weight 210,000) composed of methyl vinyl ether Z maleic anhydride Z maleic acid having a molar ratio of maleic anhydride Z maleic acid of 46Z54 was obtained as polymer (A). .
  • Methyl beryl ether Z Maleic anhydride Power copolymer (ISP, GAN TREZ AN—139) 100 mass% of water, 15 mass% of water added, and then hydrolyzed at 90 ° C for 300 minutes.
  • ISP Methyl beryl ether Z Maleic anhydride Power copolymer
  • GAN TREZ AN—139 Methyl beryl ether Z Maleic anhydride Power copolymer
  • Methyl beryl ether Z Maleic anhydride Power copolymer (ISP, GAN TREZ AN—139) 100 mass%, 15 mass% water added, 90 ° C
  • ISP Methyl beryl ether Z Maleic anhydride Power copolymer
  • GAN TREZ AN—139 Methyl beryl ether Z Maleic anhydride Power copolymer
  • Methyl beryl ether Z Maleic anhydride Power copolymer (ISP, GAN TREZ AN—139) 100 mass%, 15 mass% water added, 90 ° C
  • ISP Methyl beryl ether Z Maleic anhydride Power copolymer
  • GAN TREZ AN—139 Methyl beryl ether Z Maleic anhydride Power copolymer
  • Methyl beryl ether Z Maleic anhydride Copolymer (ISP, GAN TREZ AN—139) 100 mass%, 8 mass% water added, 90 ° C [Koo!
  • (A) the polymer is composed of maleic anhydride Z maleic acid molar ratio 56Z44 methyl vinyl ether Z maleic anhydride Z maleic acid A copolymer (molecular weight 1.08 million) was obtained.
  • Methyl beryl ether Z Maleic anhydride Copolymer (ISP, GAN TREZ AN—139) 100 mass%, 8 mass% water added, 90 ° C [Koo!
  • a copolymer (molecular weight: 1.08 million) composed of methyl vinyl ether Z maleic anhydride Z maleic acid having a molar ratio of maleic anhydride Z maleic acid of 56Z44 was obtained as polymer (A). .
  • the obtained (A) polymer 25 parts by mass, ethylene glycol (manufactured by Kanto Chemical Co., Ltd.) 23 parts by mass, dipropylene glycol (Showa Denko Co., Ltd.) 30 parts by mass, and polyethylene glycol (PEG400, Lion Corporation) 22 parts by mass were kneaded at 90 ° C for 90 minutes, and then spread into a sheet.
  • Methyl beryl ether Z Maleic anhydride Copolymer (ISP, GAN TREZ AN—139) 100 mass%, 8 mass% water added, 90 ° C [Koo!
  • a copolymer (molecular weight: 1.08 million) composed of methyl vinyl ether Z maleic anhydride Z maleic acid having a molar ratio of maleic anhydride Z maleic acid of 56Z44 was obtained as polymer (A). .
  • Methyl beryl ether Z Maleic anhydride Copolymer (ISP, GAN TREZ AN—139) Add 100 parts by weight of 1 part by weight of water and hydrolyze at 90 ° C for 180 minutes As a result, a copolymer having a molar ratio of maleic anhydride Z maleic acid of 87 Z13 and a methyl butyl ether Z maleic anhydride Z maleic acid power (molecular weight 1080,000) was obtained. 15 parts by mass of the obtained polymer and 85 parts by mass of polyethylene glycol (PEG400 Lion Co., Ltd.) were kneaded at 90 ° C. for 90 minutes, and then spread into a sheet.
  • polyethylene glycol PEG400 Lion Co., Ltd.
  • Maleic anhydride Z Maleic anhydride with a molar ratio of maleic acid 14Z86 Z Maleic anhydride Z Maleic acid Copolymer (ISP, GANTREZ S-97, molecular weight 1.5 million) 20 parts by mass 80 parts by weight of polyethylene glycol (PEG400 Lion Co., Ltd.) was kneaded at 90 ° C for 90 minutes, and then spread into a sheet.
  • ISP maleic acid 14Z86 Z Maleic anhydride Z Maleic acid Copolymer
  • Methyl beryl ether Z Maleic anhydride Copolymer (ISP, GAN TREZ AN-169) 100 mass%, 40 mass% water added, 90 ° C [Koo!
  • a copolymer of maleic anhydride and maleic anhydride having a molar ratio of maleic acid and maleic acid of 11Z89,
  • Hydroxypropylcellulose (HPC-H, Nippon Soda Co., Ltd.) 10 parts by mass and polyethylene glycol (PEG400, Lion Co., Ltd.) 90 parts by mass were kneaded at 90 ° C for 90 minutes, then in sheet form Spread out.
  • Table 1 shows the evaluation results of Examples 1A to 14A and Comparative Examples 1A to 4A.
  • Examples 1A to 14A were gel compositions having high tackiness and excellent gel-forming ability.
  • the prepared patch was cut into 10 cm ⁇ 14 cm to evaluate skin irritation.
  • the evaluation method was repeated on the inside of the forearm of five healthy panelists, and after 7 hours, and after 1 hour, the skin condition after 1 hour had passed. Observed.
  • the score was 3 points: no change from before application, 2 points: a little reddish, 1 point: very reddish, and the average score of each panel was calculated.
  • the average score is 2.5 points or more, there is no pain, the gel composition has low skin irritation, and no decrease in adhesiveness is observed after 7 hours of application. It was.
  • Comparative Examples 1A to 4A are expensive! Inability to achieve both cohesion and excellent gel-forming ability o
  • composition was kneaded at 90 ° C for 90 minutes, and then spread into a sheet.
  • Example 15A the patch had little skin irritation, high adhesiveness, and excellent gel-forming ability.
  • composition was kneaded at 90 ° C for 90 minutes, and then spread into a sheet.
  • Example 16A the patch had little skin irritation, high adhesiveness, and excellent gel-forming ability.
  • Example 1B- L0B
  • a transdermal absorption enhancer was mixed, and a binder was dispersed and mixed to obtain a gel composition.
  • the external preparation composition was applied onto the support so that the coating amount on the polyurethane film Z-knit laminated support was 0.7 (g / 70 cm 2 ). After heat treatment, the patch was cut into a size of 7 cm x 10 cm in length x width.
  • Example 1B ⁇ The components used in LOB are as follows.
  • Methyl vinyl ether Z Maleic anhydride Copolymer (ISP, GAN TREZ AN—139) 100 mass%, 8 mass% of water added, 90 ° C [Koo!
  • A As a polymer, a copolymer (weight average molecular weight 1,080,000) composed of methyl vinyl ether Z maleic anhydride Z maleic acid having a molar ratio of maleic anhydride Z maleic acid of 56Z44 was obtained. Obtained.
  • PEG300 Polyethylene glycol (weight average molecular weight 300, manufactured by Lion Corp.)
  • PEG400 Polyethylene glycol (weight average molecular weight 400, manufactured by Lion Corp.)
  • PG Propylene glycol (trade name "Propylene glycol PGjp", Arma Co., Ltd.
  • EG Ethylene glycol (trade name "Ethylene glycol (reagent)", Wako Pure Chemical Industries, Ltd.)
  • Hydroxypropylcellulose weight average molecular weight 1 million, trade name “HPC—H”, manufactured by Nippon Soda Co., Ltd.
  • Jetyl sebacate trade name “DES—SP”, manufactured by Nikko Chemicals Co., Ltd.
  • Diisopropyl adipate trade name “DID”, manufactured by Nikko Chemicals Co., Ltd.
  • Isopropyl myristate trade name “IPM—EX”, manufactured by Nikko Chemicals Co., Ltd.
  • Ololeic acid trade name “KOKOO”, manufactured by Higher Alcohol Industry Co., Ltd.
  • Example 1B Gel composition obtained from L0B Or use the patch and follow the method below
  • a patch (Example 1B etc.) was laminated on the worn skin, and a sample in the cell was taken every unit time.
  • the collected samples were subjected to high performance liquid chromatography analysis, and the amount of each medicinal component that permeated through the skin after 2 hours (medicinal component skin permeation amount, ⁇ g / cm 2 ) was determined.
  • a large amount of medicinal component skin permeation after 2 hours means that the initial percutaneous absorption is excellent.
  • Example 1B The adhesiveness of the patch prepared with L0B was evaluated based on the ball tack value when measured at an inclination angle of 30 ° according to the JIS Z-0237 test.
  • Seno ⁇ Jetinore cinnamate 10 10 10 Diisopropinole adipate 10

Abstract

Disclosed is a gel composition containing a polymer (A) having a repeating unit composed of at least one unsaturated portion and an acid anhydride portion and another repeating unit composed of at least one unsaturated portion and an acid compound portion corresponding to the acid anhydride portion, and a polyhydric alcohol (B). The polymer (A) contains the acid anhydride portion and the acid compound portion corresponding to the acid anhydride portion in a molar ratio of 15/85-85/15. This gel composition exhibits high adhesion to the skin or mucosa, and has excellent gel-forming ability.

Description

明 細 書  Specification
ゲル組成物及びその製造方法  Gel composition and method for producing the same
技術分野  Technical field
[0001] 本発明は、医療用貼付剤、創傷被覆剤、テーピング剤等の基剤として使用できるゲ ル組成物、該ゲル組成物を支持体上に展延してなる貼付剤及び該ゲル組成物の製 造方法に関する。より詳細には、本発明は、皮膚または粘膜に対する粘着性が高ぐ かつ優れたゲル形成能を有するゲル組成物等に関する。  [0001] The present invention relates to a gel composition that can be used as a base for medical patches, wound dressings, taping agents, etc., a patch obtained by spreading the gel composition on a support, and the gel composition It relates to manufacturing methods. More specifically, the present invention relates to a gel composition having high adhesiveness to the skin or mucous membrane and having an excellent gel forming ability.
背景技術  Background art
[0002] 薬剤を経皮,経粘膜吸収経路で投与する方法は、注射や経口投与と比較すると、 体液中での薬効成分有効濃度が維持されやすぐ持続性が期待できること、薬効成 分の吸収速度の調整が容易であり、副作用の危険が少ないこと、胃酸や消化酵素等 の影響や肝臓の初回通過効果による代謝の影響が少なぐ薬効成分の有効利用が 期待できること等から、近年関心が高まっている。  [0002] Compared with injection and oral administration, the method of administering a drug by the transdermal and transmucosal absorption route is that the effective concentration of the active ingredient in the body fluid is maintained and can be expected to be sustained immediately, and the absorption of the active ingredient Increased interest in recent years due to easy adjustment of speed, low risk of side effects, and effective use of medicinal ingredients that are less affected by stomach acid, digestive enzymes, etc., and less affected by metabolism due to the first-pass effect of the liver. ing.
[0003] 従来、経皮 ·経粘膜吸収経路での投与で用いる基剤としては、水にポリアクリル酸 ナトリウムやカルボキシビュルポリマー等の水溶性高分子を添カ卩したパップ剤や、 SI Sやポリイソブチレン等のゴム系やシリコン系、アクリル系の高分子に可塑剤、粘着付 与剤を添加したテープ'プラスター剤、流動パラフィンやワセリン等の油脂性基剤に ゼラチン、カルボキシメチルセルロースナトリウム等の吸水性高分子を配合した軟膏 基剤等が知られている。しかし、ノ^ブ剤には使用中に水が蒸散するため膏体が硬 化し、粘着性が低下するという問題がある。プラスター剤には経時変化は少ないが、 粘着性が強力すぎて角質層を剥離する、透湿性が劣っているため皮膚呼吸が妨げ られることにより、特に繰り返し貼付時に蒸れ'かぶれを起こす等、皮膚刺激性が高い という問題がある。また、軟膏基剤には付着性が悪いため、十分な局所滞留性がな いという問題がある。 [0003] Conventionally, as a base used for administration by the transdermal / transmucosal absorption route, a poultice prepared by adding a water-soluble polymer such as sodium polyacrylate or carboxybule polymer to water, SIS, Tapes with a plasticizer and tackifier added to rubber, silicon and acrylic polymers such as polyisobutylene, plaster agents, oily bases such as liquid paraffin and petrolatum, water absorption such as gelatin and sodium carboxymethylcellulose Ointment bases containing functional polymers are known. However, there is a problem with the nove agent because water evaporates during use, the plaster hardens and the adhesiveness decreases. Although there is little change over time with plaster agents, skin irritation, such as peeling of the stratum corneum due to too strong adhesion, and skin breathing being hindered due to poor moisture permeability, causing rashes and rashes, especially during repeated application. There is a problem of high nature. In addition, since the ointment base has poor adhesion, there is a problem that it does not have sufficient local retention.
[0004] これを解消するため、ポリアクリル酸、カルボキシメチルセルロース等の親水性ポリ マーと水に、ロジンエステル、水素添加石油榭脂、およびテルペン系榭脂からなる群 カゝら選ばれた 1種類以上の粘着付与榭脂を添加した医療用貼付剤 (特許文献 1参照 )、低級アルコールに可溶でカルボキシル基またはその塩を構造中に有した高分子 、低級アルコール、多価アルコール、金属せつけんを配合し、ゲルイ匕した粘着剤組成 物(特許文献 2参照)、ベースポリマーにメチルビニルエーテル無水マレイン酸共重 合体またはメチルビ-ルエーテルマレイン酸共重合体、架橋剤に多官能エポキシィ匕 合物を使用し、水および多価アルコールをゲルイ匕した粘着ゲル基剤(特許文献 3参 照)が提案されている。しかしながら、これらの基剤には、沸点の比較的低い水または 低級アルコールを主成分として配合して ヽるため、使用中に水または低級アルコー ルが蒸散し、粘着性、皮膚刺激性等の性能が経時で劣化するという問題がある。 [0004] To solve this problem, a hydrophilic polymer such as polyacrylic acid and carboxymethyl cellulose and water, one selected from the group consisting of rosin ester, hydrogenated petroleum resin, and terpene-based resin Medical patch containing the above tackified rosin (see Patent Document 1) ), A pressure-sensitive adhesive composition containing a polymer soluble in a lower alcohol and having a carboxyl group or a salt thereof, a lower alcohol, a polyhydric alcohol, and metal sulphate, and gelled (see Patent Document 2), Adhesive gel base using methyl vinyl ether maleic anhydride copolymer or methyl vinyl ether maleic acid copolymer as the base polymer, polyfunctional epoxy compound as the cross-linking agent, and gelling water and polyhydric alcohol (Patent Literature) 3) has been proposed. However, since these bases contain water or lower alcohol having a relatively low boiling point as the main component, water or lower alcohol evaporates during use, resulting in performance such as stickiness and skin irritation. Has a problem that it deteriorates over time.
[0005] また、架橋剤を用いて、分子内にヒドロキシル基および Zまたはカルボキシル基を 有し、かつ多価アルコール可溶性高分子で多価アルコールをゲル化した無水のゲル マトリックス (特許文献 4参照)、多価アルコールを多価アルコール可溶性高分子と力 ルポキシビ二ルポリマーとでゲルイ匕した非水系貼付剤 (特許文献 5参照)も提案され ている。これらの基剤は、主成分が多価アルコールであるため、経時での性能の劣 ィ匕はほとんどないものの、ゲル形成能を向上させるため、多価アルコールと多価アル コール可溶性高分子のほかに、架橋剤や、高吸水性高分子化合物を配合することが 必須であり、製造の操作が煩雑になる場合がある。  [0005] In addition, an anhydrous gel matrix having a hydroxyl group and a Z or carboxyl group in the molecule using a cross-linking agent and gelling the polyhydric alcohol with a polyhydric alcohol-soluble polymer (see Patent Document 4) In addition, a non-aqueous patch (see Patent Document 5) in which a polyhydric alcohol is gelled with a polyhydric alcohol-soluble polymer and a strong ropoxyvinyl polymer has also been proposed. Since these bases are mainly polyhydric alcohols, there is almost no deterioration in performance over time, but in order to improve gel forming ability, in addition to polyhydric alcohols and polyhydric alcohol soluble polymers, In addition, it is essential to add a cross-linking agent and a superabsorbent polymer compound, and the manufacturing operation may be complicated.
[0006] 多価アルコール類と、該多価アルコール類に溶解する力または該多価アルコール で膨潤するポリマーを含有することを特徴とする非水系温熱ゲル組成物 (特許文献 6 参照)も提案されている。この基剤は、主成分が多価アルコールであるため、経時劣 化がほとんどなぐ必須成分が多価アルコールとポリマーであり、製造の操作が簡便 であることが予想される。しかしながら、粘着性、およびゲル形成能に関する記載がな ぐ粘着性とゲル形成能が不充分な場合がある。  [0006] A non-aqueous thermal gel composition (see Patent Document 6) characterized by containing a polyhydric alcohol and a power that dissolves in the polyhydric alcohol or a polymer that swells with the polyhydric alcohol has also been proposed. ing. Since the main component of this base is a polyhydric alcohol, the essential components that hardly deteriorate with time are a polyhydric alcohol and a polymer, and it is expected that the manufacturing operation is simple. However, there are cases where the adhesiveness and gel-forming ability are insufficient, with no mention of adhesiveness and gel-forming ability.
[0007] 特許文献 1 :特開平 6— 254150号公報  [0007] Patent Document 1: Japanese Patent Laid-Open No. 6-254150
特許文献 2:特開平 9— 143062号公報  Patent Document 2: Japanese Patent Laid-Open No. 9-143062
特許文献 3:特開平 9 - 286891号公報  Patent Document 3: Japanese Patent Laid-Open No. 9-286891
特許文献 4:特開昭 63 - 203162号公報  Patent Document 4: Japanese Patent Laid-Open No. 63-203162
特許文献 5:特開 2003 - 113077号公報  Patent Document 5: Japanese Patent Laid-Open No. 2003-113077
特許文献 6:特開 2001— 245913号公報 発明の開示 Patent Document 6: Japanese Patent Laid-Open No. 2001-245913 Disclosure of the invention
発明が解決しょうとする課題  Problems to be solved by the invention
[0008] 従って、本発明は、皮膚または粘膜に対する粘着性が高ぐかつ優れたゲル形成 能を有するゲル組成物、および該ゲル組成物を使用する貼付剤及び該ゲル組成物 の製造方法を提供することを目的とする。  [0008] Accordingly, the present invention provides a gel composition having high adhesion to skin or mucous membrane and having an excellent gel-forming ability, a patch using the gel composition, and a method for producing the gel composition. The purpose is to do.
課題を解決するための手段  Means for solving the problem
[0009] 本発明者らは、上記の目的を達成すべく鋭意研究を重ねた結果、ポリマー中の酸 無水物部分と対応する酸ィ匕合物部分とが特定範囲にあるポリマーと多価アルコール とを併有することにより、皮膚または粘膜に対する粘着性が高ぐかつ優れたゲル形 成能を有するゲル組成物が得られることを見 ヽだし、本発明を完成した。 [0009] As a result of intensive studies to achieve the above object, the present inventors have found that a polymer and a polyhydric alcohol in which the acid anhydride portion and the corresponding acid compound portion in the polymer are in a specific range. Thus, the inventors have found that a gel composition having high adhesion to the skin or mucous membrane and having an excellent gel forming ability can be obtained, and the present invention has been completed.
すなわち、本発明は、(A)少なくとも 1つの不飽和部分と酸無水物部分とから構成 される繰り返し単位と、少なくとも 1つの不飽和部分と該酸無水物部分に対応する酸 化合物部分とから構成される繰り返し単位とを含むポリマーと、 (B)多価アルコールと を含有するゲル組成物であって、  That is, the present invention comprises (A) a repeating unit composed of at least one unsaturated portion and an acid anhydride portion, and at least one unsaturated portion and an acid compound portion corresponding to the acid anhydride portion. A gel composition comprising a polymer containing a repeating unit, and (B) a polyhydric alcohol,
(A)ポリマーが、酸無水物部分と該酸無水物部分に対応する酸化合物部分とを、 モル比にして 15Z85〜85Z 15なる割合で含むことを特徴とする前記ゲル組成物を 提供する。  (A) The gel composition is characterized in that the polymer contains an acid anhydride portion and an acid compound portion corresponding to the acid anhydride portion in a molar ratio of 15Z85 to 85Z15.
本発明はまた、支持体上に上記ゲル組成物が展延されてなる貼付剤を提供する。  The present invention also provides a patch in which the gel composition is spread on a support.
[0010] 本発明はまた、(a)少なくとも 1つの不飽和部分と酸無水物部分とから構成される繰 り返し単位を含むポリマーを加水分解して、ポリマー中に含まれる酸無水物部分と該 酸無水物部分に対応する酸ィ匕合物部分とが、モル比にして 15Z85〜85Z15であ る、(A)少なくとも 1つの不飽和部分と酸無水物部分とから構成される繰り返し単位と 、少なくとも 1つの不飽和部分と該酸無水物部分に対応する酸ィ匕合物部分とから構 成される繰り返し単位とを含むポリマーを得る工程、 [0010] The present invention also includes (a) hydrolyzing a polymer containing a repeating unit composed of at least one unsaturated portion and an acid anhydride portion, and an acid anhydride portion contained in the polymer. (A) a repeating unit composed of at least one unsaturated portion and an acid anhydride portion, wherein the acid compound portion corresponding to the acid anhydride portion is a molar ratio of 15Z85 to 85Z15, Obtaining a polymer comprising a repeating unit composed of at least one unsaturated moiety and an acid / acid compound moiety corresponding to the acid anhydride moiety,
得られた (A)ポリマーを、(B)多価アルコールに溶解させる工程、及び  A step of dissolving the obtained (A) polymer in (B) a polyhydric alcohol; and
架橋剤の不存在下、得られた混合物を加熱する工程、  Heating the resulting mixture in the absence of a crosslinking agent;
を含む、ゲル組成物の製造方法を提供する。 発明の効果 A method for producing a gel composition is provided. The invention's effect
[0011] 本発明によれば、皮膚または粘膜に対する粘着性が高ぐかつ優れたゲル形成能 を有するゲル組成物を提供することができる。本発明によればまた、性能の経時劣化 力 S小さぐ皮膚刺激を殆ど起こさない、ゲル組成物を提供することができる。  [0011] According to the present invention, it is possible to provide a gel composition having high adhesion to the skin or mucous membrane and having an excellent gel forming ability. According to the present invention, it is also possible to provide a gel composition that hardly causes skin irritation with a small deterioration power S of performance.
[0012] 本発明のゲル組成物によれば、薬効成分の経皮吸収性、好ましくは初期の経皮吸 収性に優れた貼付剤等の外用剤組成物を提供することができる。  [0012] According to the gel composition of the present invention, it is possible to provide an external preparation composition such as a patch excellent in transdermal absorbability of a medicinal component, preferably excellent in initial transdermal absorbability.
また、本発明のゲル組成物は薬効成分、特に経皮吸収し難い薬効成分の溶解性 に優れ、薬効成分の配合量を多くした外用剤組成物を提供することができる。  In addition, the gel composition of the present invention is excellent in solubility of medicinal components, particularly medicinal components that are difficult to absorb percutaneously, and can provide an external preparation composition with an increased amount of medicinal components.
本発明のゲル組成物はまた、使用性が良好であり、種々の製剤への適用が可能で ある。  The gel composition of the present invention also has good usability and can be applied to various preparations.
発明を実施するための最良の形態  BEST MODE FOR CARRYING OUT THE INVENTION
[0013] (A)少なくとも 1つの不飽和部分と酸無水物部分とから構成される繰り返し単位と、少 なくとも 1つの不飽和部分と該酸無水物部分に対応する酸化合物部分とから構成さ れる繰り返し単位とを含むポリマー [0013] (A) Consists of a repeating unit composed of at least one unsaturated moiety and an acid anhydride moiety, and at least one unsaturated moiety and an acid compound moiety corresponding to the acid anhydride moiety. Containing repeating units
本発明で使用される (A)ポリマーは、酸無水物部分と該酸無水物部分に対応する 酸ィ匕合物咅分とのモノ ktt力 15/85〜85/15、好ましくは 15/85〜80/20、より 好ましくは 20Z80〜70Z30である。このような範囲にあると、高い粘着性と優れたゲ ル形成能を兼ね備えるので好ましい。酸無水物の比率が高すぎると、高い粘着性と 優れたゲル形成能を併有するゲル組成物を得ることが困難になり、酸化合物部分の 比率が高すぎると、優れたゲル形成能を有するゲル組成物を得ることが困難になる。 なお、本発明において、酸無水物と該酸無水物部分に対応する酸化合物部分との モル比は、電位差滴定法により測定することができる。(Α)ポリマーは、少なくとも 1つ の不飽和部分のモル数と、酸無水物部分のモル数と該酸無水物部分に対応する酸 化合物部分のモル数との合計とが等し 、のが好まし 、。  The polymer (A) used in the present invention has a mono ktt force of 15/85 to 85/15, preferably 15/85 of an acid anhydride portion and an acid compound portion corresponding to the acid anhydride portion. -80/20, more preferably 20Z80-70Z30. Within such a range, it is preferable because it has both high adhesiveness and excellent gel forming ability. If the ratio of the acid anhydride is too high, it becomes difficult to obtain a gel composition having both high tackiness and excellent gel-forming ability. If the ratio of the acid compound portion is too high, the gel composition has excellent gel-forming ability. It becomes difficult to obtain a gel composition. In the present invention, the molar ratio between the acid anhydride and the acid compound portion corresponding to the acid anhydride portion can be measured by potentiometric titration. (Ii) The polymer has the same number of moles of at least one unsaturated portion as the sum of the number of moles of the acid anhydride portion and the number of moles of the acid compound portion corresponding to the acid anhydride portion. I like it.
[0014] 本発明の (Α)ポリマーの重量平均分子量は良好なゲル形成能が得られる程度に 高いことが好ましぐ例えば 1万〜 1000万、好ましくは 10万〜 500万である。この平 均分子量は、サイズ排除分離 低角度レーザー光散乱検出器法による測定値であ る。また、本発明のゲル組成物に対する当該ポリマーの配合量は、例えば、 1〜55質 量%、好ましくは 1〜40質量%、より好ましくは 1〜30質量%である。 [0014] The weight average molecular weight of the (ii) polymer of the present invention is preferably high enough to obtain good gel-forming ability, for example, 10,000 to 10,000,000, preferably 100,000 to 5,000,000. This average molecular weight is a value measured by a size exclusion separation low angle laser light scattering detector method. The blending amount of the polymer with respect to the gel composition of the present invention is, for example, 1 to 55 quality. The amount is preferably 1 to 40% by mass, more preferably 1 to 30% by mass.
[0015] 本発明の (A)ポリマーとしては、少なくとも 1つの不飽和部分がビ-ルイ匕合物である のが好ましい。ビニル化合物としては、メチルビ-ルエーテル、スチレン、エチレン、ィ ソブチレン等があげられる。このうち、メチルビ-ルエーテルが好ましい。 [0015] In the polymer (A) of the present invention, it is preferable that at least one unsaturated portion is a beluie compound. Examples of the vinyl compound include methyl vinyl ether, styrene, ethylene, isobutylene and the like. Of these, methyl beryl ether is preferred.
酸無水物部分は、無水マレイン酸部分、無水ィタコン酸部分力 なる群力 選ばれ るのが好ましい。より好ましくは、(A)ポリマーは、炭素数 3〜24のアルキルビュルェ 一テル Z無水マレイン酸 Zマレイン酸力 構成される共重合体、炭素数 3〜24のァ ルキルビュルエーテル Z無水ィタコン酸 Zィタコン酸力 構成される共重合体力 な る群力 選ばれる。さらに好ましくは、メチルビニルエーテル Z無水マレイン酸 Zマレ イン酸から構成される共重合体、メチルビ-ルエーテル Z無水ィタコン酸 Zィタコン 酸から構成される共重合体である。このうち、メチルビニルエーテル Z無水マレイン 酸,マレイン酸から構成される共重合体が最も好まし ヽ。  The acid anhydride portion is preferably selected from the group strength of maleic anhydride portion and itaconic anhydride partial force. More preferably, (A) the polymer is an alkyl butyl ether having 3 to 24 carbon atoms, a maleic anhydride, a maleic anhydride, a maleic acid copolymer, an alkyl bulle ether having 3 to 24 carbon atoms, and itaconic anhydride. Z-taconic acid power Constructed copolymer power is selected. More preferred are a copolymer composed of methyl vinyl ether Z maleic anhydride Z maleic acid and a copolymer composed of methyl vinyl ether Z itaconic anhydride Z itaconic acid. Of these, a copolymer composed of methyl vinyl ether Z maleic anhydride and maleic acid is most preferred.
[0016] 本発明の (A)ポリマーは、例えば、少なくとも 1つの不飽和部分を含むモノマーと、 酸無水物部分を含むモノマーと、該酸無水物部分に対応する酸化合物部分を含む モノマーとを共重合することにより製造することもできるし、(a)少なくとも 1つの不飽和 部分と酸無水物部分とから構成される繰り返し単位を含むポリマーを加水分解するこ とにより製造することもできる。このような (a)ポリマーとしては、例えば、 ISP社から GA NTREZ ANシリーズとして市販されているものを使用することができる。 [0016] The (A) polymer of the present invention includes, for example, a monomer containing at least one unsaturated moiety, a monomer containing an acid anhydride moiety, and a monomer containing an acid compound moiety corresponding to the acid anhydride moiety. It can also be produced by copolymerization or (a) by hydrolysis of a polymer containing a repeating unit composed of at least one unsaturated moiety and an acid anhydride moiety. As such (a) polymer, for example, those commercially available from ISP as GA NTREZ AN series can be used.
加水分解は、例えば、(a)ポリマー 100質量部に対し、 2〜: LOO質量部、好ましくは 2〜50質量部の水を添加し、 20〜100°Cの温度において、 1〜600分間、反応させ ることにより行うことができる。水の添加方法は、ポリマーを予め溶剤、例えばアセトン 、テトラヒドロフラン、ジメチルスルフォキシド、ジメチルホルムアミド等に溶解させ、そこ に水を添加してもよいし、ポリマーに水を噴霧してもよいし、ポリマーに水蒸気として 吸収させてもよい。この範囲の量の水を使用することにより、本発明のゲル組成物を 貼付剤等に製剤化しても、使用中に粘着性等が経時的に低下する程度を低くするこ とができる。得られたポリマーは、そのまま用いることもできるし、加熱、減圧乾燥等に より系内に存在する水を、ポリマーに対して 1%程度まで除去した後に用いることもで きる。 [0017] 本発明で使用する多価アルコールは、使用中に蒸散しないものが好ましぐ具体的 には、例えば、 1, 3—ブチレングリコール、エチレングリコール、プロピレングリコール 、グリセリン、トリメチロールプロパン、ジグリセリン、トリグリセリン、ポリグリセリン、ジェ チレングリコール、ジプロピレングリコール、トリエチレングリコール、ポリエチレングリコ 一ノレ (重量平均分子量 200〜2000、好ましくは 200〜600)、ポジプ Pピレング!; =3— ル(重量平均分子量 400〜4000、好ましくは 400〜1000)、ポリエチレン 'ポリプロピ レングジ 一ノレ(重量平均分子量 1000〜6000、好まし <は 1000〜3000)、ポジ才キ シエチレン硬化ヒマシ油(5E. O.〜100E. O.、好ましくは 10E. O.〜60E. O. ) およびソルビトール等が挙げられ、これらは、 1種単独または 2種以上を適宜組み合 わせて使用することができる。 Hydrolysis is performed, for example, on (a) 100 parts by mass of polymer, 2 to: LOO parts by mass, preferably 2 to 50 parts by mass of water, and at a temperature of 20 to 100 ° C. for 1 to 600 minutes, This can be done by reacting. As for the method of adding water, the polymer may be dissolved in a solvent such as acetone, tetrahydrofuran, dimethyl sulfoxide, dimethylformamide in advance, and water may be added thereto, or water may be sprayed onto the polymer. The polymer may be absorbed as water vapor. By using an amount of water in this range, even when the gel composition of the present invention is formulated into a patch or the like, it is possible to reduce the degree to which the adhesiveness or the like decreases with time during use. The obtained polymer can be used as it is, or it can be used after removing water present in the system to about 1% with respect to the polymer by heating, drying under reduced pressure or the like. [0017] Specifically, the polyhydric alcohol used in the present invention preferably does not evaporate during use. For example, 1,3-butylene glycol, ethylene glycol, propylene glycol, glycerin, trimethylolpropane, di-ethylene. Glycerin, triglycerin, polyglycerin, polyethylene glycol, dipropylene glycol, triethylene glycol, polyethylene glycol monourea (weight average molecular weight 200-2000, preferably 200-600), positive P-pilling !; = 3— (weight Average molecular weight 400-4000, preferably 400-1000), polyethylene 'polypropylene monole (weight average molecular weight 1000-6000, preferably <1000-3000), positive aged hydrogenated castor oil (5E.O.-100E) O., preferably 10E. O. to 60E. O.) and sorbitol, etc., and these may be used alone or in combination of two or more. Can be used in appropriate combinations.
[0018] この中で特に重量平均分子量が 200〜2000、より好ましくは 200〜1500、さらに 好まし <は 200〜1000、特に好まし <は 200〜600のポジエチレングジコ一ノレ力 S好ま しい。ポリエチレングリコールを使用する場合、ポリエチレングリコール以外の多価ァ ルコールを併用すると、薬効成分の経皮吸収性が向上するので特に好ましい。前記 ポリエチレングリコール以外の多価アルコールとしてはエチレングリコール、プロピレ ングリコール、 1, 3—ブチレングリコーノレ、ジエチレングリコール、ジプロピレングリコ ールなどの二価アルコールや、グリセリン、トリメチロールプロパンなどの三価アルコ ールが好ましぐエチレングリコール、プロピレングリコール、 1, 3—ブチレングリコー ル、ジエチレングリコール、ジプロピレングリコールなどの二価アルコールが特に好ま しい。併用する場合、重量平均分子量 200〜2000のポリエチレングリコールを含有 する、 2〜6価の多価アルコール混合物として使用するのが好まし!/、。  [0018] Among them, the weight average molecular weight is 200 to 2000, more preferably 200 to 1500, more preferably <is 200 to 1000, and particularly preferably <is 200 to 600. . When polyethylene glycol is used, it is particularly preferable to use a polyvalent alcohol other than polyethylene glycol because the transdermal absorbability of the medicinal component is improved. Examples of polyhydric alcohols other than polyethylene glycol include dihydric alcohols such as ethylene glycol, propylene glycol, 1,3-butylene glycol, diethylene glycol and dipropylene glycol, and trivalent alcohols such as glycerin and trimethylolpropane. Particularly preferred are dihydric alcohols such as ethylene glycol, propylene glycol, 1,3-butylene glycol, diethylene glycol and dipropylene glycol. When used in combination, it is preferably used as a dihydric or hexahydric polyhydric alcohol mixture containing polyethylene glycol having a weight average molecular weight of 200 to 2000! /.
ポリエチレングリコールと、ポリエチレングリコール以外の 2〜6価の多価アルコール との混合割合は、質量比で 1 : 9〜: LO : 0が好ましぐ 1 : 9〜9 : 1がより好ましぐ 2 : 8〜 8 : 2がさらに好ましい。このような範囲であれば、薬効成分の溶解性が高ぐ薬効成 分の経皮吸収性がより高まるので好ましい。  The mixing ratio of polyethylene glycol and divalent to 6-valent polyhydric alcohols other than polyethylene glycol is 1: 9-: LO: 0 is preferred by mass ratio 1: 9-9: 1 is more preferred 2 : 8-8: 2 is more preferable. Within such a range, the percutaneous absorbability of the medicinal component having high solubility of the medicinal component is further increased, which is preferable.
なお、重合物である多価アルコールの重量平均分子量の測定方法は化粧品原料 基準記載の滴定試験により測定することができる。  In addition, the measuring method of the weight average molecular weight of the polyhydric alcohol which is a polymer can be measured by a titration test described in the cosmetic raw material standards.
[0019] また、本発明のゲル組成物に対する当該多価アルコールの配合量は、例えば、 40 質量%〜99質量%であり、好ましくは、 50質量%〜99質量%、より好ましくは、 60質 量%〜99質量%である。また、本発明のゲル組成物に対する (A)ポリマーと多価ァ ルコールとの総量は、例えば、 60質量%以上、好ましくは 65質量%以上、より好まし くは 70質量%以上であることが望ま U、。 [0019] The blending amount of the polyhydric alcohol with respect to the gel composition of the present invention is, for example, 40 It is 50 mass%-99 mass%, Preferably, it is 50 mass%-99 mass%, More preferably, it is 60 mass%-99 mass%. Further, the total amount of the polymer (A) and the polyvalent alcohol in the gel composition of the present invention is, for example, 60% by mass or more, preferably 65% by mass or more, and more preferably 70% by mass or more. Hope U ,.
本発明の(A)ポリマーと多価アルコールとの質量の比率は、 1Z99〜55Z45であ り、好ましくは、 1Z99〜45Z55、より好ましくは、 1Z99〜35Z65である。  The mass ratio of the polymer (A) of the present invention to the polyhydric alcohol is 1Z99 to 55Z45, preferably 1Z99 to 45Z55, and more preferably 1Z99 to 35Z65.
[0020] 本発明のゲル組成物には、使用する多価アルコールに溶解または膨潤する高分 子を任意に配合することができる。ここで、溶解とは、高分子 1質量%の多価アルコー ル溶液が均一になることを意味する。膨潤とは、一定質量の多価アルコールと混合し た場合に、高分子が多価アルコールを吸収して体積を増す状態をいい、この高分子 多価アルコール混合物の質量が、混合前の高分子質量の 2倍以上である場合を いう。高分子は、多価アルコールに溶解または膨潤してゲルィ匕することが好ましい。 具体的には、例えば、ヒドロキシプロピルセルロース、ヒドロキシェチルセルロース、ポ リビュルピロリドン、カルボキシビ-ルポリマー、(メタ)アクリル酸 Z (メタ)アクリル酸ェ ステル共重合体、 N—メタクリロイルェチルー N, N ジメチルアンモ-ゥムー α— Ν— メチルカルボキシベタイン重合体、ポリアクリル酸、ポリ酢酸ビュル、ポリビュルアルコ ール、ポリ Ν ビュルァセトアミド、ポリメトキシポリエチレングリコール (メタ)アタリレート 、ポリフエノキシポリエチレングリコール (メタ)アタリレート、ポリヒドロキシェチル (メタ) アタリレート、ポリヒドロキシプロピル (メタ)アタリレート、ポリアクリルアミド、アクリル酸 Ζアクリルアミド Ζアクリル酸ェチル共重合体、メタアクリル酸コポリマー、およびイソ ブチレン等を挙げることができ、これらは、 1種単独または 2種以上を適宜組み合わせ て使用することができる。 [0020] The gel composition of the present invention may optionally contain a polymer that dissolves or swells in the polyhydric alcohol used. Here, dissolution means that a polyvalent alcohol solution of 1% by mass of a polymer becomes uniform. Swelling refers to a state in which a polymer absorbs polyhydric alcohol and increases its volume when mixed with a certain mass of polyhydric alcohol, and the mass of this polyhydric alcohol mixture is the polymer before mixing. This is when the mass is twice or more. The polymer is preferably gelled by dissolving or swelling in a polyhydric alcohol. Specifically, for example, hydroxypropyl cellulose, hydroxyethyl cellulose, polypyrrolidone, carboxyvinyl polymer, (meth) acrylic acid Z (meth) acrylic acid ester copolymer, N-methacryloyl ethyl N, N Dimethylammomu α- Ν— Methyl carboxybetaine polymer, polyacrylic acid, polyacetic acid butyl, polybutyl alcohol, poly ビ ュ bulucacetamide, polymethoxypolyethylene glycol (meth) acrylate, polyphenoxypolyethylene Glycol (meth) acrylate, polyhydroxyethyl (meth) acrylate, polyhydroxypropyl (meth) acrylate, polyacrylamide, acrylic acid Ζ acrylamide ェ ethyl acrylate copolymer, methacrylic acid copolymer, and isobutyl It can be exemplified emissions, and these may be used singly or in combination of two or more appropriately.
[0021] 本発明のゲル組成物には、任意に粘着剤、結合剤、薬効成分、経皮吸収向上剤、 その他の有効成分、香料、および色素等の添加物を配合することができる。粘着剤、 結合剤及びこれらの混合物からなる群から選ばれる少なくとも 1種を含有すると、本 発明のゲル組成物の粘着性を向上させることができるので好ましい。また、本発明の ゲル組成物が薬効成分を含有するときには、薬効を持続させることができるので好ま しい。経皮吸収向上剤を含有すると、本発明のゲル組成物が薬効成分を含有する場 合、薬効成分の経皮吸収性、特に初期の経皮吸収性が向上するので好ましい。本 発明で使用する添加物は、多価アルコールに溶解または分散可能であれば、特に 制限されない。有効成分としては、例えば、温感用有効成分、冷感用有効成分、末 梢循環促進作用剤、消炎鎮痛成分、血行促進剤、局所麻酔剤、発汗促進剤、水虫 薬、抗菌 ·殺菌成分、抗菌 ·滅菌剤、美白成分、皮脂抑制剤、角質溶解剤、頸椎捻 挫用有効成分、収れん成分等がある。これらは、 1種単独または 2種以上を適宜組み 合わせて使用することができる。 [0021] The gel composition of the present invention may optionally contain additives such as pressure-sensitive adhesives, binders, medicinal ingredients, transdermal absorption enhancers, other active ingredients, perfumes, and pigments. It is preferable to contain at least one selected from the group consisting of a pressure-sensitive adhesive, a binder, and a mixture thereof because the pressure-sensitive adhesiveness of the gel composition of the present invention can be improved. Further, when the gel composition of the present invention contains a medicinal component, it is preferable because the medicinal effect can be sustained. When the transdermal absorption enhancer is contained, the gel composition of the present invention contains a medicinal component. It is preferable because the percutaneous absorbability of the medicinal component, particularly the initial percutaneous absorbability, is improved. The additive used in the present invention is not particularly limited as long as it can be dissolved or dispersed in a polyhydric alcohol. Examples of active ingredients include warm sensation active ingredient, cool sensation active ingredient, terminal circulation promoting agent, anti-inflammatory analgesic ingredient, blood circulation promoter, local anesthetic agent, antiperspirant, athlete's foot drug, antibacterial / bactericidal ingredient, Antibacterial and sterilizing agents, whitening ingredients, sebum suppressants, keratolytic agents, active ingredients for cervical sprains, and astringent ingredients. These can be used alone or in combination of two or more.
[0022] く粘着剤〉 [0022] Ku adhesives>
粘着剤としては、スチレン Zイソプレン Zスチレンブロック共重合体 (SIS)、ポリイソ ブチレン (PIB)等のエラストマ一に、ロジンエステル、脂環族系榭脂、ポリテルペン榭 脂等の粘着性付与剤を配合したゴム系粘着剤;ポリアクリル酸、ポリアクリル酸塩 (好 ましくはナトリウム塩)、アクリル酸 Zメタクリル酸共重合体等のアクリル系粘着剤;ポリ シロキサンの誘導体等のシリコン系粘着剤;アルキルビニルエーテル Z無水マレイン 酸共重合体等のビニルエーテル系粘着剤;アクリル酸エステル Z酢酸ビニルコポリマ 一等の酢酸ビュル系粘着剤等があげられる。これら粘着剤は、 1種単独で用いてもよ ぐ 2種以上を併用してもよい。アクリル系粘着剤、ビニルエーテル系粘着剤がより好 ましく用いられる。  Adhesives such as rosin ester, alicyclic resin, and polyterpene resin are mixed with elastomers such as styrene Z isoprene Z styrene block copolymer (SIS) and polyisobutylene (PIB). Rubber adhesives; acrylic adhesives such as polyacrylic acid, polyacrylate (preferably sodium salt), acrylic acid Z methacrylic acid copolymer; silicone adhesives such as polysiloxane derivatives; alkyl Examples include vinyl ether-based adhesives such as vinyl ether Z maleic anhydride copolymer; and butyl acetate-based adhesives such as acrylic ester Z vinyl acetate copolymer. These pressure-sensitive adhesives may be used alone or in combination of two or more. Acrylic adhesives and vinyl ether adhesives are more preferably used.
[0023] 上記粘着剤の質量平均分子量は、 10000〜 10000000であること力好ましく、 10 0000〜5000000であること力より好まし!/ヽ。  [0023] The mass average molecular weight of the pressure-sensitive adhesive is preferably 10,000 to 10,000,000, more preferably 10,000 to 50,000,000!
粘着剤の配合量は、組成物中、 1〜78質量%が好ましぐ 5〜75質量%がより好ま しい。該範囲の下限値以上であれば、ゲル組成物の使用部位への密着性が充分に 得られ、上限値以下であれば、ゲル組成物の使用部位力 の剥離性が良好となる。  The blending amount of the pressure-sensitive adhesive is preferably 1 to 78% by mass, more preferably 5 to 75% by mass in the composition. If it is at least the lower limit of the range, sufficient adhesion to the use site of the gel composition is obtained, and if it is at most the upper limit, the peelability of the use site force of the gel composition is good.
[0024] <結合剤 >  [0024] <Binder>
結合剤としては、カルボキシビ二ルポリマー、アルギン酸、ポリビュルアルコール、ポ リビニルピロリドン、カルボキシメチルセルロース、ヒドロキシプロピルセルロース、ヒド ロキシプロピルメチルセルロース等が挙げられる。中でも、カルボキシビ二ルポリマー 、ヒドロキシプロピルセルロースが好ましぐヒドロキシプロピルセルロースがより好まし い。 上記結合剤の重量平均分子量は、 10000〜 10000000であること力 S好ましく、 50 000〜5000000であることがより好ましい。なお、前記結合剤の重量平均分子量はExamples of the binder include carboxyvinyl polymer, alginic acid, polybutyl alcohol, polyvinyl pyrrolidone, carboxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose and the like. Among these, carboxyvinyl polymer and hydroxypropylcellulose are preferred, and hydroxypropylcellulose is more preferred. The weight average molecular weight of the binder is preferably 10,000 to 100,000,000, more preferably 50,000 to 5,000,000. The weight average molecular weight of the binder is
、ゲルパーミエーシヨンクロマトグラフィー法や光散乱法により測定することができるが 、特にカルボキシポリマーの場合は、ゲルパーミエーシヨンクロマトグラフィー法により ポリエチレンオキサイド換算した値、ヒドロキシプロピルセルロースの場合はゲルパー ミエーシヨンクロマトグラフィー法によりプルラン換算した値、ポリビュルピロリドンの場 合は光散乱法により測定した値を用いる。 It can be measured by gel permeation chromatography method or light scattering method. In particular, in the case of a carboxy polymer, a value converted into polyethylene oxide by gel permeation chromatography method, and in the case of hydroxypropyl cellulose, gel permeation. Use the value calculated by pullulan conversion by the Chillon chromatography method, or the value measured by the light scattering method in the case of polybulurpyrrolidone.
これら結合剤は、 1種単独で用いてもよぐ 2種以上を併用してもよい。  These binders may be used alone or in combination of two or more.
結合剤の配合量は、組成物中、 1〜30質量%が好ましぐ 1〜20質量%がより好ま しい。該範囲であれば、塗布した部位での組成物の滞留性が良好となり、薬効の持 続性を高めることができる。  The blending amount of the binder is preferably 1 to 30% by mass and more preferably 1 to 20% by mass in the composition. If it is this range, the retention property of the composition in the applied part will become favorable, and the sustainability of a medicinal effect can be improved.
粘着剤と結合剤との混合物を使用する場合、混合物の配合量は、組成物中、 1〜7 8質量%が好ましぐ 5〜75質量%がより好ましい。  When a mixture of an adhesive and a binder is used, the blending amount of the mixture is preferably 1 to 78% by mass, more preferably 5 to 75% by mass in the composition.
[0025] <薬効成分 > <Medication>
薬効成分としては、インドメタシン、フエルビナク、ケトプロフェン、フルルビプロフエ ン、ジクロフェナク等の非ステロイド系抗炎症剤及びそのエステル誘導体;ジフェンヒ ドラミン等の抗ヒスタミン剤、塩酸イソプレナリン等の中枢神経作用薬、ェストラジオ一 ル及びテストステロン等のホルモン剤;アスピリン、ァセトァミノフェン、イブプロフェン 等の鎮痛剤;リン酸ジソピラミド等の抗不整脈用剤、塩酸トラゾリン等の冠血管拡張剤 、リドカイン等の局所麻酔剤、塩化スキサメトニゥム等の筋弛緩剤、クロトリマゾール等 の抗真菌剤、フルォロウラシル等の抗悪性腫瘍剤、塩酸タムスロシン等の排尿障害 剤、ジァゼパム等の抗てんかん剤、メシル酸ブロモクリプチン等の抗パーキンソン病 剤、フロセミド、クロ-ジン等の降圧剤、ニトログリセリン及び硝酸イソソルビド等の血 管拡張剤、ニコチン等の禁煙補助剤、ッロブテール等の気管支拡張剤、フエノバル ピタール、トリァゾラム等の催眠鎮静剤、フルフエナジン、テオリタジン等の精神安定 剤;ビタミン A、ビタミン E、ビタミン K、ォクトチアシン、リボフラビン酪酸エステル等の ビタミン剤;プロスタグランジン類、スコポラミン、フェンタニール等が挙げられる。  The medicinal properties include non-steroidal anti-inflammatory drugs such as indomethacin, fuel binac, ketoprofen, flurbiprofen, diclofenac, and ester derivatives thereof; antihistamines such as diphenhydramine, central nervous system drugs such as isoprenaline hydrochloride, estradiol and testosterone Hormonal agents; analgesics such as aspirin, acetaminophen, ibuprofen; antiarrhythmic agents such as disopyramide phosphate; coronary vasodilators such as tolazoline hydrochloride; local anesthetics such as lidocaine; muscle relaxants such as skisamethonium chloride; Antifungal agents such as clotrimazole, anti-neoplastic agents such as fluorouracil, dysuria such as tamsulosin hydrochloride, antiepileptic agents such as diazepam, antiparkinsonian agents such as bromocriptine mesylate, antihypertensive agents such as furosemide and clodine Vasodilators such as nitroglycerin and isosorbide nitrate, smoking cessation aids such as nicotine, bronchodilators such as lobbutale, hypnotic sedatives such as phenovalpital and triazolam, tranquilizers such as fluphenazine and theoritadine; vitamin A, vitamin Vitamins such as E, vitamin K, octothiacin, riboflavin butyrate; prostaglandins, scopolamine, fentanyl, etc.
[0026] 温感用有効成分には、例えば、トウガラシエキス、トウガラシチンキ、カブサイシン、 黄檗エキス、肉桂、ジンジャーエキス、ショウキヨウアルコールエキス、カンタリスチンキ[0026] The active ingredients for warm feeling include, for example, red pepper extract, red pepper tincture, kabusaicin, Twilight extract, meat katsura, ginger extract, ginger alcohol extract, cantalis tincture
、ニコチン酸べンジルエステル、ビタミン E、ボルネオール、 dl—カンフル、 1—メントー ル、ハツ力油、ユーカリ油、サリチル酸メチル、サリチル酸グリコール、ヮ-リルアルコ ール誘導体、ノ-ル酸ヮ-リルアミド、バニリルアルコールアルキルエーテル、コショウ 科植物抽出エキス、ァザミ属植物抽出エキス、ァレチアザミ属植物抽出エキス、チョウ ジ油、オイゲノール誘導体等がある。これらの成分を添加すると、皮膚に対する局所 刺激または誘導刺激を利用して血行を促進し、温感を得ることができる。冷感用有効 成分には、例えば、メントール、メントールグリセロールエーテル、およびそれら化合 物のエステル等の誘導体、 N-ェチル -p-3-メンタン-カルボキシアミド、ハツ力油、力 ンフル等がある。これらの成分を添加すると、皮膚に対する局所刺激又は誘導刺激 を利用して、冷感を得ることができる。 , Nicotinic acid benzyl ester, vitamin E, borneol, dl-camphor, 1-menthol, heart force oil, eucalyptus oil, methyl salicylate, glycol salicylate, リ ル -allyl alcohol derivatives, ヮ -rilamide of norlate, vanillyl Examples include alcohol alkyl ethers, pepper family plant extracts, sage genus plant extracts, argentia genus plant extracts, clove oil, and eugenol derivatives. When these components are added, blood circulation can be promoted using a local or induced stimulus to the skin, and a warm feeling can be obtained. Active ingredients for cooling sensation include, for example, menthol, menthol glycerol ether, and derivatives of these compounds such as esters, N-ethyl-p-3-menthane-carboxamide, heart force oil, and force flu. When these components are added, a cool sensation can be obtained by utilizing local or induced irritation to the skin.
[0027] 末梢循環促進作用剤には、例えば、酢酸トコフ ロール等がある。消炎鎮痛成分に は、例えば、サリチル酸、サリチル酸メチル、サリチル酸グリコール、ジフェンヒドラミン 、マレイン酸クロルフエ-ラミン、グリチルリチン酸アンモ-ゥム、グリチルリチン酸ジカ リウム、グリチルリチン酸、グリチルリチン酸ステアリル、 13—ダリチルレチン酸、ァラン トイン、ァズレン、 ε—アミノカプロン酸、ヒドロコルチゾン、パントテン酸カルシウム、パ ントテン酸ェチルエーテル、酢酸ヒドロコーチゾン、ノ-ル酸ヮ-ルアミド、ジフエ-ル ヒドラミン、インドメタシン、ケトプロフェン、フルルビプロフェン、イブプロフェン、スプロ フェン、ロキソプロフェン、ザルトプロフェン、ピロキシカム、フエルビナク、アルニカチ ンキ、甘草、黄連、シコン、西洋ノコギリ草、ヒリハリ草、アロエ、ビタミン Ε酢酸エステル 等がある。頸椎捻挫用有効成分には、例えば、アミノアルコキシビベンジル類等があ る。 [0027] The peripheral circulation promoting agent includes, for example, tocolol acetate. Anti-inflammatory analgesic components include, for example, salicylic acid, methyl salicylate, glycol salicylate, diphenhydramine, chlorfelamamine maleate, ammonium glycyrrhizinate, dicalium glycyrrhizinate, glycyrrhizic acid, stearyl glycyrrhizinate, 13-darlicylretinoic acid, , Azulene, ε -aminocaproic acid, hydrocortisone, calcium pantothenate, ethyl pantothenate, hydrocortisone acetate, nor-hydroxamide, diphenol hydramine, indomethacin, ketoprofen, flurbiprofen, ibuprofen, suprofen, Loxoprofen, Zaltoprofen, Piroxicam, Fuerbinac, Arnica tincture, Licorice, Yellow ream, Sikon, Western sawtooth grass, Spiral grass, Aloe, Vitamin There is an ester, and the like. Examples of active ingredients for cervical spine include aminoalkoxybibenzyls.
[0028] 血行促進剤には、例えば、センプリエキス、セファランチン、ビタミン Εおよびその誘 導体、 Ί オリザノール、ペパーミント油、テレビン油、チヨウジ油、ゲラ-オール油、 チモール油、ウイキヨゥ油、ベルガモット油、ァニス油、ラベンダー油、ブラックぺッパ 一油、ベニノ ナ油、ァノレ-力エキス、マロニエエキス、ェンメイソゥエキス、ボダイジュ エキス、メリッサエキス、 Ν ェチル ρ— 3—メンタン一カルボキシアミド等がある。局 所麻酔剤には、例えば、ロートエキス、ジブ力イン、プロ力イン、リドカイン等がある。収 れん成分には、タンニン含有成分が好ましくは使用され、例えば、酸化亜鉛、硫酸亜 鉛、アラントインヒドロキシアルミニウム、塩化アルミニウム、硫酸アルミニウム、スルホ 石炭酸亜鉛、タンニン酸、クェン酸、乳酸、ォゥパク末、ハマメリス、ォドリコ草、白樺、 ダイォゥ等がある。発汗促進剤には、好ましくは無機塩が使用される。例えば、焼石 こう、塩化カルシウム、無水塩化カルシウム、塩化マグネシウム、無水塩化マグネシゥ ム、炭酸カルシウム、無水炭酸カルシウム、硫酸ナトリウム、無水硫酸ナトリウム、硫酸 マグネシウム、無水硫酸マグネシウム、水酸化ナトリウム、水酸ィ匕カリウム、塩化ナトリ ゥム、塩ィ匕カリウム、ゼォライト、モンモリロナイト、スメクタイト、カオリン、タルク、粘土 鉱物、その他各種塩類等がある。 [0028] Examples of the blood circulation promoter include senpri extract, cephalanthin, vitamin Ε and its derivatives, Ί oryzanol, peppermint oil, turpentine oil, thiodi oil, geraol oil, thymol oil, wikiyou oil, bergamot oil, anise Oil, Lavender oil, Black pepper oil, Beninona oil, Anole extract, Maronier extract, Enmeiso extract, Bodaige extract, Melissa extract, ェ ethyl ρ-3-menthane monocarboxamide, etc. Examples of local anesthetics include funnel extract, jib force-in, pro force-in, and lidocaine. Yield Tannin-containing components are preferably used as the brick component. There are abalone grass, white birch, Daio etc. An inorganic salt is preferably used as the perspiration promoter. For example, calcined gypsum, calcium chloride, anhydrous calcium chloride, magnesium chloride, anhydrous magnesium chloride, calcium carbonate, anhydrous calcium carbonate, sodium sulfate, anhydrous sodium sulfate, magnesium sulfate, anhydrous magnesium sulfate, sodium hydroxide, potassium hydroxide Sodium chloride, potassium chloride, zeolite, montmorillonite, smectite, kaolin, talc, clay minerals, and various other salts.
[0029] 殺菌 ·抗菌成分には、例えば、ピロタトンオラミン、シクロピロタスオラミン、塩化ベン ザルコ-ゥム、塩化べンゼトニゥム、ハロカルバン、塩酸クロ口へキシジン、ジンクピリ チオン、フエノール、トリクロロカルバ-リド、ダルコン酸クロルへキシジン、塩化セチル ピリジ-ゥム、イソプロピルメチルフエノール、アラントイン、抗プラスミン剤( ε—ァミノ カプロン酸、トラネキサム酸)、ジヒドロコレステロール、当帰エキス、力ミツレ(ァズレン 含有)、ユーカリ油などの精油類、ヒノキチオール等がある。水虫薬には、例えば、薬 効成分であるキヌハダ (Callophyllis flabellulata)水抽出物、硝酸ミコナゾール、その他 鎮痒剤である塩酸ジフェンヒドラミン、マレイン酸クロルフエ-ラミン、カンファー、およ びラボライト等が使用される。  [0029] Sterilization · Antibacterial components include, for example, pyrotatone olamine, cyclopilotas olamine, benzalkonium chloride, benzethonium chloride, halocarban, clohexhexidine hydrochloride, zinc pyrithione, phenol, trichlorocarba -Lido, chlorhexidine dalconate, cetyl pyridinium chloride, isopropylmethylphenol, allantoin, anti-plasmin agent (ε-aminocaproic acid, tranexamic acid), dihydrocholesterol, tonic extract, force mitre (containing azulene), There are essential oils such as eucalyptus oil and hinokitiol. As the athlete's foot drug, for example, quinuhada (Callophyllis flabellulata) water extract, which is an active ingredient, miconazole nitrate, and other antipruritic agents, diphenhydramine hydrochloride, chlorfelamine maleate, camphor, and labrite are used.
[0030] 抗菌'殺菌剤には、例えば、ジンクピリチオン、トリクロロカルバ-リド、トリクロサン、 アロエエキス、ニンジンエキス、カンゾゥエキス、ォォバタエキス、力ミツレエキス、ビヮ 抽出液、水溶性セリウム塩、ァビエチン酸、ピマール酸、ビス(2—ピリジンチオール 1 オキサイド)亜鉛、ピリジンチオン塩、ヒスタミン 2受容体きっ抗薬、ビタミン E酢 酸エステル、パントテュルェチルエーテル、クェン酸トリェチルエステル、メチォニン、 シスチン、システィンなどの含硫アミノ酸およびその塩酸塩、シナモン'クローブ 'タイ ム 'ペンゾイン'オークモス 'バニラからの抽出物、亜鉛ピリチオン、 10—ァリール一 1 , 8—ジヒドロキシアントロン、安息香酸ナトリウム、アントシァニン、アントシァ-ジン類 、ピぺラジン誘導体、尿酸、ぺタイン類、ルチン、 1—ヒドロキシ— 2—ピリドン類、亜硫 酸イオン発生水溶性塩、アルミノケィ酸ナトリウム、油溶性甘草抽出物、およびラポラ イト等がある。当該抗菌'殺菌剤は、一般に、ふけ防止剤として使用され得る。 [0030] Antibacterial 'bactericidal agents include, for example, zinc pyrithione, trichlorocarbalide, triclosan, aloe extract, carrot extract, licorice extract, wolverine extract, force extract, birch extract, water-soluble cerium salt, abietic acid, pimaric acid, Sulfur containing bis (2-pyridinethiol 1 oxide) zinc, pyridinethione salt, histamine 2 receptor antagonist, vitamin E acetate, pantothruethyl ether, citrate triethyl ester, methionine, cystine, cysteine, etc. Amino acids and their hydrochlorides, extracts from cinnamon 'clove' time 'penzoin' oak moss' vanilla, zinc pyrithione, 10-aryl 1,8-dihydroxyanthrone, sodium benzoate, anthocyanins, anthocyanins, pipettes Razine derivative, uric acid, Tyne acids, rutin, 1-hydroxy - 2-pyridones, sulfite ion generating water-soluble salts, sodium Aruminokei acid, oil-soluble licorice extract, and Rapora There is it. Such antibacterial 'disinfectants can generally be used as antidandruff agents.
[0031] 美白成分、皮脂抑制剤、角質溶解剤等は、主に化粧品として利用する場合に使用 され得る。美白成分には、例えば、アルブチン、エラグ酸、コウジ酸、ハイドロキノン、 ビタミン C、プラセンタエキス、酸化チタン、ホソバノトサカモドキ (Callophyllis japonica) 水抽出物、およびクロトサカモドキ (Callophyllis adhaerens)水抽出物等がある。また、 皮脂抑制剤、角質溶解剤には、例えば、エストラジオール、エストロン、ェチニルエス トラジオール、ビタミン B6、ィォゥ、レゾルシン、塩化ベンザルコ-ゥム、塩化べンゼト 二ゥム、ハロカルバン、 2, 4, 4—トリクロ口一 2—ヒドロキシフエノール、硫化セレン、ぺ ンタデカン酸、ペンタデカン酸誘導体、各種ビタミン類等がある。  [0031] A whitening component, a sebum inhibitor, a keratolytic agent, and the like can be used mainly when used as a cosmetic. Whitening ingredients include, for example, arbutin, ellagic acid, kojic acid, hydroquinone, vitamin C, placenta extract, titanium oxide, water extract of Callophyllis japonica, and water extract of Callophyllis adhaerens. There is. Examples of sebum inhibitors and keratolytic agents include estradiol, estrone, ethynylestradiol, vitamin B6, io, resorcin, benzalkonium chloride, benzethonium chloride, halocarban, 2, 4, 4 —Trichrome mouthpieces 2-hydroxyphenol, selenium sulfide, pentadecanoic acid, pentadecanoic acid derivatives, various vitamins, etc.
[0032] 中でも、本発明の効果が特に顕著なことから水難溶性薬効成分が好ましぐインドメタ シン、フエルビナク、ケトプロフェン、フルルビプロフェン、ジクロフェナク等の非ステロ イド系抗炎症剤;エストラジオール及びテストステロン等のホルモン剤、フロセミド、クロ 二ジン等の降圧剤、ニトログリセリン及び硝酸イソソルビド等の血管拡張剤、ニコチン 等の禁煙補助剤、ッロブテール等の気管支拡張剤、スコポラミン、フェンタニールが より好ましい。さらに好ましくは、インドメタシン、フエルビナク、ケトプロフェン、フルル ビプロフェンである。これら薬効成分は、 1種単独で用いてもよぐ 2種以上を併用して ちょい。  [0032] Among them, non-steroid anti-inflammatory agents such as indomethacin, fuerbinac, ketoprofen, flurbiprofen, diclofenac and the like, which are preferably poorly water-soluble medicinal ingredients because the effects of the present invention are particularly remarkable; estradiol, testosterone, etc. Hormonal agents, antihypertensive agents such as furosemide and clonidine, vasodilators such as nitroglycerin and isosorbide nitrate, smoking cessation aids such as nicotine, bronchodilators such as lolobtail, scopolamine and fentanyl are more preferred. More preferred are indomethacin, fuel binac, ketoprofen and flurbiprofen. These medicinal ingredients may be used alone or in combination of two or more.
なお、「水難溶性薬効成分」とは、難溶性の指標として、例えば日局の性状試験に 準じて水に対する溶解性を示す時に、「極めて溶けにく!、」又は「ほとんど溶けな!/、」 の用語が用いられる薬効成分のことを 、う。  In addition, “poorly water-soluble medicinal ingredient” is an index of sparingly soluble, for example, when it shows solubility in water according to the Japanese pharmacy property test, “very insoluble!” Or “almost insoluble! /, "The medicinal ingredient for which the term" is used.
本発明のゲル組成物における薬効成分の配合量は、当業者であれば適宜設定す ることが可能であり、組成物中、 0. 05〜70質量%程度が好ましい。  The compounding amount of the medicinal component in the gel composition of the present invention can be appropriately set by those skilled in the art, and is preferably about 0.05 to 70% by mass in the composition.
[0033] <経皮吸収向上剤 > [0033] <Transdermal absorption enhancer>
経皮吸収向上剤としては、下記式(1):  As a transdermal absorption enhancer, the following formula (1):
(R2OOC) - R1 - R3 (1) (R 2 OOC)-R 1 -R 3 (1)
[式中、 R1は炭素数 3〜36の炭化水素基であり、 R2は炭素数 1〜20の炭化水素基で あり、 R3は水素原子又は— COOR4で R4は炭素数 1〜: L0の炭化水素基である。 ] で表されるエステルがあげられる。 R1は、炭素数 3〜36、好ましくは 4〜20の炭化水素基を示し、直鎖状であっても分 岐鎖状であってもよぐ飽和であっても不飽和であってもよい。炭素数がこのような範 囲にあると、薬効成分の経皮吸収性及びポリエチレングリコールを含む多価アルコー ルに対する溶解性に優れるので好ましい。 R3が水素原子のときは、炭素数は 10〜3 6であることが好ましぐ COOR4のときは、炭素数は 3〜20であることが好ましい。 [Wherein R 1 is a hydrocarbon group having 3 to 36 carbon atoms, R 2 is a hydrocarbon group having 1 to 20 carbon atoms, R 3 is a hydrogen atom or —COOR 4 and R 4 is 1 carbon atom. ~: It is a hydrocarbon group of L0. ] The ester represented by these is mention | raise | lifted. R 1 represents a hydrocarbon group having 3 to 36 carbon atoms, preferably 4 to 20 carbon atoms, which may be linear, branched or saturated or unsaturated. Good. A carbon number in this range is preferable because it is excellent in transdermal absorbability of medicinal ingredients and solubility in polyhydric alcohols including polyethylene glycol. When R 3 is a hydrogen atom, the number of carbon atoms is preferably 10 to 36. When COOR 4 is selected, the number of carbon atoms is preferably 3 to 20.
R2は、炭素数 1〜20、好ましくは 1〜18の炭化水素基を示し、直鎖状であっても分 岐鎖状であってもよぐ飽和であっても不飽和であってもよい。また、 R3が水素原子の ときは、炭素数は 1〜18であることが好ましい。 R3が一 COOR4のときは、炭素数は 1 〜10であることが好ましぐより好ましくは 1〜6、さらに好ましくは 1〜3である。 R 2 represents a hydrocarbon group having 1 to 20 carbon atoms, preferably 1 to 18 carbon atoms, which may be linear, branched or saturated or unsaturated. Good. In addition, when R 3 is a hydrogen atom, the number of carbon atoms is preferably 1-18. When R 3 is one COOR 4, the number of carbon atoms is preferably from it preferably instrument is 1-10 1-6, more preferably 1-3.
R3は、水素原子又は COOR4で R4は炭素数 1〜10、好ましくは 1〜8の炭化水素 基を示し、該炭化水素基は直鎖状であっても分岐鎖状であってもよぐ飽和であって も不飽和であってもよい。なお、 R2と R4は、互いに同じであっても異なっていてもよい R 3 represents a hydrogen atom or COOR 4 and R 4 represents a hydrocarbon group having 1 to 10 carbon atoms, preferably 1 to 8 carbon atoms, and the hydrocarbon group may be linear or branched. It may be saturated or unsaturated. R 2 and R 4 may be the same as or different from each other.
[0034] 経皮吸収向上剤の具体例としては、セバシン酸ジェチル、セバシン酸ジイソプロピ ル、アジピン酸ジェチル、アジピン酸ジイソプロピル、ォレイン酸ォレイル、ミリスチン 酸イソプロピル、パルミチン酸イソプロピル、リノール酸ェチル、リノール酸イソプロピ ル等が挙げられる。中でも、セバシン酸ジェチル、セバシン酸ジイソプロピル、アジピ ン酸ジイソプロピル、ォレイン酸ォレイル、ミリスチン酸イソプロピルが好ましい。セバ シン酸ジェチルが特に好まし!/、。 [0034] Specific examples of the transdermal absorption enhancer include decyl sebacate, diisopropyl sebacate, decyl adipate, diisopropyl adipate, oleyl oleate, isopropyl myristate, isopropyl palmitate, ethyl linoleate, isopropyl linoleate. And the like. Of these, decyl sebacate, diisopropyl sebacate, diisopropyl adipate, oleyl oleate, and isopropyl myristate are preferred. Especially preferred is Jetyl Sebacate! /.
これら経皮吸収向上剤は、 1種単独で用いてもよぐ 2種以上を併用してもよい。 経皮吸収向上剤の配合量は、組成物中、 1〜50質量%が好ましぐ 3〜40質量% 力 り好ましぐ 5〜30質量%がさらに好ましぐ 10〜30質量%が特に好ましい。該 範囲であれば、薬効成分の経皮吸収性が良好となる。  These transdermal absorption enhancers may be used alone or in combination of two or more. The blending amount of the transdermal absorption enhancer is preferably 1 to 50% by weight in the composition, 3 to 40% by weight, more preferably 5 to 30% by weight, and even more preferably 10 to 30% by weight. preferable. Within such a range, the transdermal absorbability of the medicinal component is good.
[0035] 上記多価アルコールと経皮吸収向上剤との混合割合は、質量比で 1: 9〜9: 1が好 ましく 2 : 8〜8 : 2がより好ましい。該範囲であれば、薬効成分の溶解性と薬効成分の 経皮吸収性がともに優れたものとなる。 [0035] The mixing ratio of the polyhydric alcohol and the transdermal absorption enhancer is preferably 1: 9 to 9: 1 in terms of mass ratio, more preferably 2: 8 to 8: 2. Within this range, both the solubility of the medicinal component and the transdermal absorbability of the medicinal component are excellent.
経皮吸収促進剤としては、例えば、クロタミトン、ベンジルアルコール等を挙げること ができ、これらは 1種単独または 2種以上適宜組み合わせて使用することができる。 [0036] 香料には、例えば、ァミルシンナミックアルデヒド、ベンジルアセテート、 p—tertブ チノレシクロへキシノレアセテート、シクラセット、シクラプロップ、ガラキソリッド、ベディォ ン、オレンジ油等がある。また、色素は、特に限定されず、法定色素ハンドブック記載 の色素を配合することができ、例えば、赤 2号、緑色 3号、青色 1号、だいだい 402号 、黄色 401号、紫色 401号等がある。 Examples of the transdermal absorption enhancer include crotamiton and benzyl alcohol, and these can be used singly or in appropriate combination of two or more. [0036] Examples of the fragrances include amylcinnamic aldehyde, benzyl acetate, p-tert butynolecyclohexenole acetate, cyclaset, cyclaprop, garaki solid, bedeon, orange oil and the like. The dye is not particularly limited, and the dyes described in the Legal Dye Handbook can be blended. For example, Red 2, Green 3, Blue 1, Dai 402, Yellow 401, Purple 401, etc. is there.
[0037] 本発明のゲル組成物は、(A)ポリマーを (B)多価アルコールに溶解させ、多価アル コールと架橋反応し、ゲルを形成することにより製造することが出来る。本発明におい て、(A)ポリマーを (B)多価アルコールに溶解させ、架橋反応させる際に、溶解'架 橋反応を促進させるために、加熱処理を行うことが好ましい。加熱は、(A)ポリマーと (B)多価アルコールとを練合ないし混練しながら実施してもよぐまた、(A)ポリマーと (B)多価アルコールとを含有するスラリーを不織布等の支持体に塗布した後に行つ てもよい。加熱温度は、使用する(B)多価アルコールによって異なる力 (B)多価ァ ルコールの沸点を超えない範囲で、例えば、 20°C〜250°C程度であり、好ましくは、 40°C〜200°C程度、より好ましくは、 60°C〜180°C程度であることが望ましい。加熱 時間は、例えば 10分〜 10時間、好ましくは 30分〜 4時間である。  [0037] The gel composition of the present invention can be produced by dissolving (A) a polymer in (B) a polyhydric alcohol, and performing a crosslinking reaction with the polyhydric alcohol to form a gel. In the present invention, when (A) the polymer is dissolved in (B) polyhydric alcohol and subjected to a crosslinking reaction, it is preferable to perform a heat treatment in order to promote the dissolution / crosslinking reaction. The heating may be performed while kneading or kneading (A) the polymer and (B) the polyhydric alcohol. In addition, the slurry containing (A) the polymer and (B) the polyhydric alcohol is made into a nonwoven fabric or the like. This may be done after application to the support. The heating temperature is different depending on the (B) polyhydric alcohol used. (B) In the range not exceeding the boiling point of the polyhydric alcohol, for example, about 20 ° C to 250 ° C, preferably 40 ° C to It is desirable that the temperature be about 200 ° C, more preferably about 60 ° C to 180 ° C. The heating time is, for example, 10 minutes to 10 hours, preferably 30 minutes to 4 hours.
[0038] 本発明のゲル組成物は、その用途、剤型が特に制限されものでなぐ例えば、皮膚 、毛髪、口腔 (粘膜を含む。)、爪等に塗布できる外用剤組成物として使用することが できる。剤型としては、特に限定されず、貼付剤(医療用貼付剤、創傷被覆剤、テー ビング剤、フットケアシート剤、ノック剤、マスク剤)、軟膏剤、ゲル剤、塗布剤等が挙 げられ、特に貼付剤が好ましい。外用剤組成物の塗布量としては、用いる薬効成分 や結合剤等の種類によるが、例えば 0. 01〜: Lg/cm2程度が好ましい。外用剤組成 物は、常法によって製造することができる。 [0038] The gel composition of the present invention is not particularly limited in its use and dosage form. For example, it is used as an external preparation composition that can be applied to skin, hair, oral cavity (including mucous membranes), nails and the like. Is possible. The dosage form is not particularly limited, and includes patches (medical patches, wound dressings, tabing agents, foot care sheet agents, knock agents, mask agents), ointments, gels, and coating agents. In particular, a patch is preferred. The coating amount of the external preparation composition is preferably about 0.01 to about Lg / cm 2 , for example, depending on the types of medicinal ingredients and binders used. The composition for external use can be produced by a conventional method.
本発明では、貼付剤とは、上記ゲル組成物を支持体上に展延したものであり、展延 方法は、特に限定されず、公知の装置を用いて行うことができ、例えば、ロールコー ター、ナイフコーター、スリットダイコーター、グラビアコーター等を用いることができる 。また、支持体としては、公知のものを使用することができ、例えば、紙、編布、織布、 不織布、高分子フィルム、またはそれらの積層体等を挙げることができる。編布、織布 、不織布、高分子フィルムの素材としては、ポリエステル、ポリプロピレン、レーヨン、ポ リ塩化ビュル、ポリエチレン、ポリウレタン、ポリウレタン'塩ビ共重合フィルム等を挙げ ることができる。上記ゲル組成物を支持体に展延する際の展延量は、特に制限される もので ίまな!/ヽカ f列えば、、 0. 001〜lg/cm2、好ましく ίま、 0. 003〜0. 5g/cm2、 より好ましくは、 0. 005〜0. 2gZcm2である。 In the present invention, the patch is obtained by spreading the gel composition on a support, and the spreading method is not particularly limited, and can be performed using a known apparatus, for example, a roll coater. A knife coater, a slit die coater, a gravure coater or the like can be used. Moreover, as a support body, a well-known thing can be used, For example, paper, a knitted fabric, a woven fabric, a nonwoven fabric, a polymer film, or those laminated bodies etc. can be mentioned. Materials for knitted fabric, woven fabric, non-woven fabric, and polymer film include polyester, polypropylene, rayon, Examples include butyl chloride, polyethylene, polyurethane, and polyurethane 'vinyl chloride copolymer film. The amount of spreading when the gel composition is spread on the support is not particularly limited, and it is 0.001 to 1 lg / cm 2 , preferably 0. 003 to 0.5 g / cm 2 , more preferably 0.005 to 0.2 gZcm 2 .
[0039] なお、本発明の貼付剤は、上記ゲル組成物を展延した後、薬効成分の揮発防止、 粘着面の保護等を目的として、必要に応じて、当該貼付剤のゲル組成物側上部にフ エイシング層を設け、被覆してもよい。フェイシング層には、貼付剤を保護できるもの であれば何でもよいが、例えば、ポリプロピレンフィルム、ポリ塩化ビュルフィルム、ポ リエチレンフィルム、ポリエチレンテレフタレートフィルム等のプラスチックフィルムや剥 離紙等がある。貼付剤は、その後、適当な大きさに裁断して用いることができる。裁断 方法は、スリツターによる裁断、押し切りによる裁断もしくはこれらの組み合わせ、また は打ち抜き裁断法等、 Vヽかなる裁断方法を用いてもよ!ヽ。 [0039] It should be noted that the patch of the present invention, after spreading the gel composition, is used as needed for the purpose of preventing volatilization of medicinal ingredients, protecting the adhesive surface, etc. A facing layer may be provided on the top and covered. The facing layer is not particularly limited as long as it can protect the patch, and examples thereof include plastic films such as polypropylene film, polychlorinated bull film, polyethylene film, and polyethylene terephthalate film, and release paper. The patch can then be cut into an appropriate size and used. The cutting method may be any cutting method such as slitting, cutting by push-cutting, or a combination of these, or the punching cutting method.
本発明の貼付剤は、ボールタック値 CFIS Z— 0237試験に準じ、傾斜角 30° で測 定したときの値)が 4〜32、好ましくは 6〜30となるように粘着力を調整することが好ま しい。該範囲の下限値以上であれば、貼付剤の使用部位への密着性が充分に得ら れ、上限値以下であれば、皮膚刺激が少なく貼付剤を剥がすことができる。  According to the ball tack value CFIS Z-0237 test, the adhesive patch of the present invention has an adhesive strength adjusted to 4 to 32, preferably 6 to 30, when measured at an inclination angle of 30 °. Is preferred. If it is at least the lower limit of the range, sufficient adhesion to the site of use of the patch can be obtained, and if it is not more than the upper limit, the patch can be peeled off with little skin irritation.
貼付剤における粘着力は、粘着剤の選択や配合量の制御などにより調整すること ができる。  The adhesive strength of the patch can be adjusted by selecting the adhesive and controlling the blending amount.
以下、実施例、比較例を挙げて本発明をより詳細に説明するが、本発明はこれらの 実施例に限定されるものではな 、。  Hereinafter, the present invention will be described in more detail with reference to Examples and Comparative Examples, but the present invention is not limited to these Examples.
実施例  Example
[0040] (実施例 1A〜16A、比較例 1A〜4A)  (Examples 1A to 16A, Comparative Examples 1A to 4A)
実施例 1A〜: L 1A、 13A及び 14Aおよび比較例 1A〜4Aは、各成分をベンチ-一 ダー(PNV— 1、(株)日立製作所製)で練合して得たゲル組成物を、ポリエステル- ット (東宝繊維 (株)製)上に 0. lgZcm2となるように、ロールコーター (花栄機械工業 (株)製)で均一に展延して、シートにした。 Examples 1A to: L 1A, 13A and 14A and Comparative Examples 1A to 4A are gel compositions obtained by kneading each component with a bench-kinder (PNV-1, manufactured by Hitachi, Ltd.) polyester - Tsu DOO such that 0. lgZcm 2 on (Toho Textile Co., Ltd.), and uniformly spread by a roll coater (manufactured by Hanae machinery industry Co.), and the sheet.
実施例 12Aは、各成分をベンチ-一ダー (PNV—1、(株)日立製作所製)で室温 にお 、て 5分間練合して得たスラリーを、ポリエステルニット (東宝繊維 (株)製)上に 0 . lgZcm2となるように、ロールコーター (花栄機械工業 (株)製)で均一に塗布した後 に加熱して調製した。下記方法により、上記各ゲル組成物のゲル形成能、および上 記各貼付剤の粘着性につ!、て評価した。 Example 12A is a polyester knit (manufactured by Toho Textile Co., Ltd.), in which each component was kneaded for 5 minutes at room temperature with a bench-top (PNV-1, manufactured by Hitachi, Ltd.). ) Up 0 It was prepared by heating after uniformly coating with a roll coater (manufactured by Kaei Machine Industry Co., Ltd.) so that lgZcm 2 was obtained. The gel forming ability of each gel composition and the adhesiveness of each patch were evaluated by the following methods.
[0041] (ゲル形成能評価法) [0041] (Gel forming ability evaluation method)
ゲル組成物は、貯蔵弾性率の周波数依存性が低いものほど、ゲル形成能は高いこ とが知られている。そこで、本発明者らは、作製したゲル組成物の貯蔵弾性率が、測 定周波数の変化によってどの程度影響するかを調査し、ゲル形成能を評価した。貯 蔵弾性率は 25°Cにおいて応力制御型レオメーター(Rheo— Stress RS— 100、 H aake社製)で測定し、周波数が 0. IradZsecの貯蔵弾性率 (G' (0. 1) )と lOradZ secの貯蔵弾性率 (G,(10) )との比(G,(10) ZG' (0. 1) )の値から、ゲル形成能を 評価した。評価は G' (10) ZG' (0. 1)が 0. 67以上 1. 5未満を「◎」、 0. 5以上 0. 6 7未満、および 1. 5以上 2未満を「〇」、 0. 5未満、および 2以上を「X」とした。  It is known that the gel composition has a higher gel-forming ability as the storage elastic modulus has a lower frequency dependency. Therefore, the present inventors investigated how much the storage elastic modulus of the prepared gel composition is affected by the change of the measurement frequency, and evaluated the gel forming ability. The storage elastic modulus was measured with a stress-controlled rheometer (Rheo—Stress RS—100, manufactured by Haake) at 25 ° C, and the storage elastic modulus (G ′ (0. 1)) with a frequency of 0. IradZsec. The gel-forming ability was evaluated from the value of the ratio (G, (10) ZG ′ (0.1)) to the storage elastic modulus (G, (10)) of lOradZ sec. Evaluation is G '(10) ZG' (0.1) is 0.67 or more and less than 1.5 `` ◎ '', 0.5 or more and less than 0.67, and 1.5 or more and less than 2 is `` ◯ '', Less than 0.5 and 2 or more were designated as “X”.
[0042] (粘着性評価法) [0042] (Adhesion evaluation method)
作製したシートをテクスチャーアナライザー(TA—XT2、 Stable Micro System s社製)で、評価した。コラーゲン膜で覆った直径 20mmのプローブを、 10秒間 100g 荷重でシートに粘着させ、その後、剥離速度 lOmmZsecで剥離するときの剥離仕 事を粘着性として評価した。評価は lOOOg'mm以上を「◎」、 500g'mm以上 1000 8' 111111未満を「〇」、 50(^ ' 111111未満を「 」とした。  The produced sheet was evaluated with a texture analyzer (TA-XT2, manufactured by Stable Micro Systems). A probe with a diameter of 20 mm covered with a collagen film was adhered to the sheet with a load of 100 g for 10 seconds, and then the peeling operation when peeling at a peeling speed of lOmmZsec was evaluated as tackiness. The evaluation was “O” for lOOOg'mm or more, “◯” for 500g′mm or more and less than 1000 8'111111, and “” for 50 (^ '111111 or less.
[0043] (実施例 1A) [0043] (Example 1A)
メチルビ-ルエーテル Z無水マレイン酸力 構成される共重合体 (ISP社製、 GAN TREZ AN— 139) 100質量咅 こ、 8質量咅の水を添カロし、 90°C【こお!ヽて 180分 加水分解させることにより、(A)ポリマーとして、無水マレイン酸 Zマレイン酸のモル 比が 56Z44のメチルビ-ルエーテル Z無水マレイン酸 Zマレイン酸から構成される 共重合体 (分子量 108万)を得た。  Methyl beryl ether Z Maleic anhydride Copolymer (ISP, GAN TREZ AN—139) 100 mass%, 8 mass% water added, 90 ° C [Koo! By hydrolyzing, a copolymer (molecular weight: 1.08 million) composed of methyl vinyl ether Z maleic anhydride Z maleic acid having a molar ratio of maleic anhydride Z maleic acid of 56Z44 was obtained as polymer (A). .
得られた (A)ポリマー 25質量部とポリエチレングリコール (PEG400、ライオン (株) 製) 75質量部とを、 90分間 90°Cで練合した後、シート状に展延した。  25 parts by mass of the obtained (A) polymer and 75 parts by mass of polyethylene glycol (PEG400, manufactured by Lion Corporation) were kneaded at 90 ° C. for 90 minutes, and then spread into a sheet.
[0044] (実施例 2A) [0044] (Example 2A)
メチルビ-ルエーテル Z無水マレイン酸力 構成される共重合体 (ISP社製、 GAN TREZ AN— 139) 100質量咅 こ、 15質量咅の水を添カロし、 90°C【こお!ヽて 300分 間加水分解させることにより、(A)ポリマーとして、無水マレイン酸 Zマレイン酸のモ ル比が 27Z73のメチルビ-ルエーテル Z無水マレイン酸 Zマレイン酸から構成され る共重合体 (分子量 108万)を得た。 Methyl beryl ether Z Maleic anhydride Power copolymer (ISP, GAN TREZ AN—139) 100 mass% of water, 15 mass% of water added, and then hydrolyzed at 90 ° C for 300 minutes. (A) As a polymer, maleic anhydride Z maleic acid Thus, a copolymer (molecular weight: 1.08 million) composed of methyl beryl ether Z maleic anhydride Z maleic acid having a molar ratio of 27Z73 was obtained.
得られた (A)ポリマー 25質量部とポリエチレングリコール (PEG400、ライオン (株) 製) 75質量部とを、 90分間 90°Cで練合した後、シート状に展延した。  25 parts by mass of the obtained (A) polymer and 75 parts by mass of polyethylene glycol (PEG400, manufactured by Lion Corporation) were kneaded at 90 ° C. for 90 minutes, and then spread into a sheet.
[0045] (実施例 3A) [0045] (Example 3A)
メチルビ-ルエーテル Z無水マレイン酸力 構成される共重合体 (ISP社製、 GAN TREZ AN— 169) 100質量部に、 4質量部の水を添カ卩し、 90°Cにおいて 180分間 加水分解させることにより、(A)ポリマーとして、無水マレイン酸 Zマレイン酸のモル 比が 70Z30のメチルビ-ルエーテル Z無水マレイン酸 Zマレイン酸から構成される 共重合体 (分子量 198万)を得た。  Methyl beryl ether Z Maleic anhydride Copolymer (ISP, GAN TREZ AN—169) Add 100 parts by mass of 4 parts by mass of water and hydrolyze at 90 ° C for 180 minutes As a result, a copolymer (molecular weight: 1.98 million) composed of methyl vinyl ether Z maleic anhydride Z maleic acid having a maleic anhydride Z maleic acid molar ratio of 70Z30 was obtained as the polymer (A).
得られた (A)ポリマー 10質量部とポリエチレングリコール (PEG400、ライオン (株) 製) 90質量部とを、 90分間 90°C練合した後、シート状に展延した。  10 parts by mass of the obtained (A) polymer and 90 parts by mass of polyethylene glycol (PEG400, manufactured by Lion Corporation) were kneaded at 90 ° C. for 90 minutes, and then spread into a sheet.
[0046] (実施例 4A) [Example 4A]
メチルビ-ルエーテル Z無水マレイン酸力 構成される共重合体 (ISP社製、 GAN TREZ AN— 169) 100質量部に、 3質量部の水を添カ卩し、 90°Cにおいて 180分間 加水分解させることにより、(A)ポリマーとして、無水マレイン酸 Zマレイン酸のモル 比が 74Z26のメチルビ-ルエーテル Z無水マレイン酸 Zマレイン酸から構成される 共重合体 (分子量 198万)を得た。  Methyl vinyl ether Z Maleic anhydride Copolymer (ISP, GAN TREZ AN—169) Add 100 parts by weight of 3 parts by weight of water and hydrolyze at 90 ° C for 180 minutes As a result, a copolymer (molecular weight: 1.98 million) composed of methyl vinyl ether Z maleic anhydride Z maleic acid having a molar ratio of maleic anhydride Z maleic acid of 74Z26 was obtained as the polymer (A).
得られた (A)ポリマー 15質量部とポリエチレングリコール (PEG400、ライオン (株) 製) 85質量部とを、 90分間 90°C練合した後、シート状に展延した。  15 parts by mass of the obtained (A) polymer and 85 parts by mass of polyethylene glycol (PEG400, manufactured by Lion Corporation) were kneaded at 90 ° C. for 90 minutes, and then spread into a sheet.
[0047] (実施例 5A) [0047] (Example 5A)
メチルビ-ルエーテル Z無水マレイン酸力 構成される共重合体 (ISP社製、 GAN TREZ AN— 169) 100質量咅 こ、 2質量咅の水を添カロし、 90°C【こお!ヽて 120分 加水分解させることにより、(A)ポリマーとして、無水マレイン酸 Zマレイン酸のモル 比が 77Z23のメチルビ-ルエーテル Z無水マレイン酸 Zマレイン酸から構成される 共重合体 (分子量 198万)を得た。 得られた (A)ポリマー 20質量部とポリエチレングリコール (PEG400、ライオン (株) 製) 80質量部とを、 90分間 90°C練合した後、シート状に展延した。 Methyl vinyl ether Z Maleic anhydride Copolymer (ISP, GAN TREZ AN—169) 100 mass%, add 2 mass% of water, and add 90 ° C. By hydrolyzing, a copolymer (molecular weight 1.98 million) composed of methyl vinyl ether Z maleic anhydride Z maleic acid having a molar ratio of maleic anhydride Z maleic acid of 77Z23 was obtained as (A) polymer. . 20 parts by mass of the obtained (A) polymer and 80 parts by mass of polyethylene glycol (PEG400, manufactured by Lion Corporation) were kneaded at 90 ° C. for 90 minutes, and then spread into a sheet.
[0048] (実施例 6A) [0048] (Example 6A)
メチルビ-ルエーテル Z無水マレイン酸力 構成される共重合体 (ISP社製、 GAN TREZ AN— 169) 100質量咅 こ、 2質量咅の水を添カロし、 90oC【こお!ヽて 30分 加水分解させることにより、(A)ポリマーとして、無水マレイン酸 Zマレイン酸のモル 比が 84Z16のメチルビ-ルエーテル Z無水マレイン酸 Zマレイン酸から構成される 共重合体 (分子量 198万)を得た。 Methyl beryl ether Z Maleic anhydride Copolymer (ISP, GAN TREZ AN—169) 100 mass%, 2 mass% of water is added, and 90 o C By hydrolyzing, a copolymer (molecular weight: 1.98 million) composed of methyl vinyl ether Z maleic anhydride Z maleic acid having a molar ratio of maleic anhydride Z maleic acid of 84Z16 was obtained as (A) polymer. .
得られた (A)ポリマー 25質量部とポリエチレングリコール (PEG400、ライオン (株) 製) 75質量部とを、 90分間 90°C練合した後、シート状に展延した。  25 parts by mass of the obtained (A) polymer and 75 parts by mass of polyethylene glycol (PEG400, manufactured by Lion Corporation) were kneaded at 90 ° C. for 90 minutes, and then spread into a sheet.
[0049] (実施例 7A) [0049] (Example 7A)
メチルビ-ルエーテル Z無水マレイン酸力 構成される共重合体 (ISP社製、 GAN TREZ AN— 139) 100質量咅 こ、 20質量咅の水を添カロし、 90°C【こお!ヽて 450分 間加水分解させることにより、(A)ポリマーとして、無水マレイン酸 Zマレイン酸のモ ル比が 17Z83のメチルビ-ルエーテル Z無水マレイン酸 Zマレイン酸から構成され る共重合体 (分子量 108万)を得た。  Methyl beryl ether Z Maleic anhydride Powered copolymer (ISP, GAN TREZ AN—139) 100 mass%, 20 mass% of water is added, and 90 ° C [Koo! By subjecting to partial hydrolysis, a copolymer (molecular weight 1.08 million) composed of methyl vinyl ether Z maleic anhydride Z maleic acid having a molar ratio of maleic anhydride to maleic anhydride of 17Z83 is obtained as the polymer (A). Obtained.
得られた (A)ポリマー 20質量部とポリエチレングリコール (PEG400、ライオン (株) 製) 80質量部とを、 90分間 90°C練合した後、シート状に展延した。  20 parts by mass of the obtained (A) polymer and 80 parts by mass of polyethylene glycol (PEG400, manufactured by Lion Corporation) were kneaded at 90 ° C. for 90 minutes, and then spread into a sheet.
[0050] (実施例 8A) [0050] (Example 8A)
メチルビ-ルエーテル Z無水マレイン酸力 構成される共重合体 (ISP社製、 GAN TREZ AN— 119) 100質量咅 こ、 25質量咅の水を添カロし、 20°C【こお!ヽて 60分 加水分解させることにより、(A)ポリマーとして、無水マレイン酸 Zマレイン酸のモル 比が 46Z54のメチルビ-ルエーテル Z無水マレイン酸 Zマレイン酸から構成される 共重合体 (分子量 21万)を得た。  Methyl beryl ether Z Maleic anhydride Powered copolymer (ISP, GAN TREZ AN—119) 100 mass%, 25 mass% water added, 20 ° C [Koo! By hydrolyzing, a copolymer (molecular weight 210,000) composed of methyl vinyl ether Z maleic anhydride Z maleic acid having a molar ratio of maleic anhydride Z maleic acid of 46Z54 was obtained as polymer (A). .
得られた (A)ポリマー 20質量部とポリエチレングリコール (PEG400、ライオン (株) 製) 80質量部とを、 90分間 90°C練合した後、シート状に展延した。  20 parts by mass of the obtained (A) polymer and 80 parts by mass of polyethylene glycol (PEG400, manufactured by Lion Corporation) were kneaded at 90 ° C. for 90 minutes, and then spread into a sheet.
[0051] (実施例 9A) [0051] (Example 9A)
メチルビ-ルエーテル Z無水マレイン酸力 構成される共重合体 (ISP社製、 GAN TREZ AN— 139) 100質量咅 こ、 15質量咅の水を添カロし、 90°C【こお!ヽて 300分 間加水分解させることにより、(A)ポリマーとして、無水マレイン酸 Zマレイン酸のモ ル比が 27Z73のメチルビ-ルエーテル Z無水マレイン酸 Zマレイン酸から構成され る共重合体 (分子量 108万)を得た。 Methyl beryl ether Z Maleic anhydride Power copolymer (ISP, GAN TREZ AN—139) 100 mass% of water, 15 mass% of water added, and then hydrolyzed at 90 ° C for 300 minutes. (A) As a polymer, maleic anhydride Z maleic acid Thus, a copolymer (molecular weight: 1.08 million) composed of methyl beryl ether Z maleic anhydride Z maleic acid having a molar ratio of 27Z73 was obtained.
得られた (A)ポリマー 3質量部、ヒドロキシプロピルセルロース(HPC— H、 ハーキュ レス社製) 10質量部、およびポリエチレングリコール (PEG300、ライオン (株)製) 87 質量部を、 90分間 90°C練合した後、シート状に展延した。  The obtained (A) polymer 3 parts by mass, hydroxypropylcellulose (HPC-H, Hercules) 10 parts by mass, and polyethylene glycol (PEG300, Lion Co.) 87 parts by mass for 90 minutes at 90 ° C After kneading, it was spread into a sheet.
[0052] (実施例 10A) [0052] (Example 10A)
メチルビ-ルエーテル Z無水マレイン酸力 構成される共重合体 (ISP社製、 GAN TREZ AN— 139) 100質量咅 こ、 15質量咅の水を添カロし、 90°C【こお!ヽて 300分 間加水分解させることにより、(A)ポリマーとして、無水マレイン酸 Zマレイン酸のモ ル比が 27Z73のメチルビ-ルエーテル Z無水マレイン酸 Zマレイン酸から構成され る共重合体 (分子量 108万)を得た。  Methyl beryl ether Z Maleic anhydride Power copolymer (ISP, GAN TREZ AN—139) 100 mass%, 15 mass% water added, 90 ° C By partial hydrolysis, (A) a polymer (molecular weight: 1.08 million) composed of methyl vinyl ether Z maleic anhydride Z maleic acid having a molar ratio of maleic anhydride Z maleic acid of 27Z73 is obtained. Obtained.
得られた (A)ポリマー 20質量部とグリセリン (新日本理ィ匕 (株)製) 80質量部とを、 1 20分間 90°C練合した後、シート状に展延した。  20 parts by mass of the obtained (A) polymer and 80 parts by mass of glycerin (manufactured by Nippon Shin-ryo Co., Ltd.) were kneaded at 90 ° C. for 120 minutes, and then spread into a sheet.
[0053] (実施例 11 A) [0053] (Example 11 A)
メチルビ-ルエーテル Z無水マレイン酸力 構成される共重合体 (ISP社製、 GAN TREZ AN— 139) 100質量咅 こ、 15質量咅の水を添カロし、 90°C【こお!ヽて 300分 間加水分解させることにより、(A)ポリマーとして、無水マレイン酸 Zマレイン酸のモ ル比が 27Z73のメチルビ-ルエーテル Z無水マレイン酸 Zマレイン酸から構成され る共重合体 (分子量 108万)を得た。  Methyl beryl ether Z Maleic anhydride Power copolymer (ISP, GAN TREZ AN—139) 100 mass%, 15 mass% water added, 90 ° C By partial hydrolysis, (A) a polymer (molecular weight: 1.08 million) composed of methyl vinyl ether Z maleic anhydride Z maleic acid having a molar ratio of maleic anhydride Z maleic acid of 27Z73 is obtained. Obtained.
得られた (A)ポリマー 10質量部とポリグリセリン( # 750、阪本薬品工業 (株)製) 90 質量部とを、 90分間 90°C練合した後、シート状に展延した。  10 parts by mass of the obtained (A) polymer and 90 parts by mass of polyglycerin (# 750, manufactured by Sakamoto Pharmaceutical Co., Ltd.) were kneaded at 90 ° C. for 90 minutes, and then spread into a sheet.
[0054] (実施例 12A) [0054] (Example 12A)
メチルビ-ルエーテル Z無水マレイン酸力 構成される共重合体 (ISP社製、 GAN TREZ AN— 139) 100質量咅 こ、 8質量咅の水を添カロし、 90°C【こお!ヽて 180分 加水分解させることにより、(A)ポリマーとして、無水マレイン酸 Zマレイン酸のモル 比が 56Z44のメチルビ-ルエーテル Z無水マレイン酸 Zマレイン酸から構成される 共重合体 (分子量 108万)を得た。 Methyl beryl ether Z Maleic anhydride Copolymer (ISP, GAN TREZ AN—139) 100 mass%, 8 mass% water added, 90 ° C [Koo! By hydrolyzing, (A) the polymer is composed of maleic anhydride Z maleic acid molar ratio 56Z44 methyl vinyl ether Z maleic anhydride Z maleic acid A copolymer (molecular weight 1.08 million) was obtained.
得られた (A)ポリマー 25質量部、プロピレングリコール(昭和電工 (株)製) 45質量 部、およびポリエチレングリコール (PEG400、ライオン (株)製) 30質量部を塗布した 後、 90分間 90°Cで加熱し調製した。  (A) 25 parts by mass of the polymer, 45 parts by mass of propylene glycol (manufactured by Showa Denko KK), and 30 parts by mass of polyethylene glycol (PEG400, lion Corporation) were applied, and then 90 ° C for 90 minutes. Prepared by heating.
[0055] (実施例 13 A) [Example 13 A]
メチルビ-ルエーテル Z無水マレイン酸力 構成される共重合体 (ISP社製、 GAN TREZ AN— 139) 100質量咅 こ、 8質量咅の水を添カロし、 90°C【こお!ヽて 180分 加水分解させることにより、(A)ポリマーとして、無水マレイン酸 Zマレイン酸のモル 比が 56Z44のメチルビ-ルエーテル Z無水マレイン酸 Zマレイン酸から構成される 共重合体 (分子量 108万)を得た。  Methyl beryl ether Z Maleic anhydride Copolymer (ISP, GAN TREZ AN—139) 100 mass%, 8 mass% water added, 90 ° C [Koo! By hydrolyzing, a copolymer (molecular weight: 1.08 million) composed of methyl vinyl ether Z maleic anhydride Z maleic acid having a molar ratio of maleic anhydride Z maleic acid of 56Z44 was obtained as polymer (A). .
得られた (A)ポリマー 25質量部、エチレングリコール(関東ィ匕学 (株)製) 23質量部 、ジプロピレングリコール(昭和電工 (製)) 30質量部、およびポリエチレングリコール( PEG400、ライオン (株)製) 22質量部を、 90分間 90°C練合した後、シート状に展延 した。  The obtained (A) polymer 25 parts by mass, ethylene glycol (manufactured by Kanto Chemical Co., Ltd.) 23 parts by mass, dipropylene glycol (Showa Denko Co., Ltd.) 30 parts by mass, and polyethylene glycol (PEG400, Lion Corporation) 22 parts by mass were kneaded at 90 ° C for 90 minutes, and then spread into a sheet.
[0056] (実施例 14A)  [0056] (Example 14A)
メチルビ-ルエーテル Z無水マレイン酸力 構成される共重合体 (ISP社製、 GAN TREZ AN— 139) 100質量咅 こ、 8質量咅の水を添カロし、 90°C【こお!ヽて 180分 加水分解させることにより、(A)ポリマーとして、無水マレイン酸 Zマレイン酸のモル 比が 56Z44のメチルビ-ルエーテル Z無水マレイン酸 Zマレイン酸から構成される 共重合体 (分子量 108万)を得た。  Methyl beryl ether Z Maleic anhydride Copolymer (ISP, GAN TREZ AN—139) 100 mass%, 8 mass% water added, 90 ° C [Koo! By hydrolyzing, a copolymer (molecular weight: 1.08 million) composed of methyl vinyl ether Z maleic anhydride Z maleic acid having a molar ratio of maleic anhydride Z maleic acid of 56Z44 was obtained as polymer (A). .
得られた (A)ポリマー 25質量部とポリエチレングリコール (PEG400、ライオン (株) 製) 75質量部とを、 180分間 40°Cで練合した後、シート状に展延した。  25 parts by mass of the obtained (A) polymer and 75 parts by mass of polyethylene glycol (PEG400, manufactured by Lion Corporation) were kneaded at 40 ° C. for 180 minutes, and then spread into a sheet.
[0057] (比較例 1A) [0057] (Comparative Example 1A)
メチルビ-ルエーテル Z無水マレイン酸力 構成される共重合体 (ISP社製、 GAN TREZ AN— 139) 100質量部に、 1質量部の水を添カ卩し、 90°Cにおいて 180分間 加水分解させることにより、無水マレイン酸 Zマレイン酸のモル比が 87Z13のメチル ビュルエーテル Z無水マレイン酸 Zマレイン酸力も構成される共重合体 (分子量 10 8万)を得た。 得られたポリマー 15質量部と、ポリエチレングリコール (PEG400 ライオン (株)製) 85質量部とを、 90分間 90°Cで練合した後、シート状に展延した。 Methyl beryl ether Z Maleic anhydride Copolymer (ISP, GAN TREZ AN—139) Add 100 parts by weight of 1 part by weight of water and hydrolyze at 90 ° C for 180 minutes As a result, a copolymer having a molar ratio of maleic anhydride Z maleic acid of 87 Z13 and a methyl butyl ether Z maleic anhydride Z maleic acid power (molecular weight 1080,000) was obtained. 15 parts by mass of the obtained polymer and 85 parts by mass of polyethylene glycol (PEG400 Lion Co., Ltd.) were kneaded at 90 ° C. for 90 minutes, and then spread into a sheet.
[0058] (比較例 2A) [0058] (Comparative Example 2A)
無水マレイン酸 Zマレイン酸のモル比が 14Z86のメチルビ-ルエーテル Z無水マ レイン酸 Zマレイン酸力 構成される共重合体 (ISP社製、 GANTREZ S— 97、分 子量 150万) 20質量部と、ポリエチレングリコール(PEG400 ライオン (株)製) 80質 量部とを、 90分間 90°Cで練合した後、シート状に展延した。  Maleic anhydride Z Maleic anhydride with a molar ratio of maleic acid 14Z86 Z Maleic anhydride Z Maleic acid Copolymer (ISP, GANTREZ S-97, molecular weight 1.5 million) 20 parts by mass 80 parts by weight of polyethylene glycol (PEG400 Lion Co., Ltd.) was kneaded at 90 ° C for 90 minutes, and then spread into a sheet.
[0059] (比較例 3A) [0059] (Comparative Example 3A)
メチルビ-ルエーテル Z無水マレイン酸力 構成される共重合体 (ISP社製、 GAN TREZ AN- 169) 100質量咅 こ、 40質量咅の水を添カロし、 90°C【こお!ヽて 720分 間加水分解させることにより、無水マレイン酸 Zマレイン酸のモル比が 11Z89のメチ ルビ-ルエーテル Z無水マレイン酸 Zマレイン酸力 構成される共重合体 (分子量 1 Methyl beryl ether Z Maleic anhydride Copolymer (ISP, GAN TREZ AN-169) 100 mass%, 40 mass% water added, 90 ° C [Koo! By subjecting it to partial hydrolysis, a copolymer of maleic anhydride and maleic anhydride having a molar ratio of maleic acid and maleic acid of 11Z89,
98万)を得た。 980,000).
得られたポリマー 20質量部と、ポリエチレングリコール (PEG400 ライオン (株)製) 80質量部とを、 90分間 90°Cで練合した後、シート状に展延した。  20 parts by mass of the obtained polymer and 80 parts by mass of polyethylene glycol (PEG400 Lion Co., Ltd.) were kneaded at 90 ° C. for 90 minutes, and then spread into a sheet.
[0060] (比較例 4A) [0060] (Comparative Example 4A)
ヒドロキシプロピルセルロース(HPC— H、 日本曹達 (株)製) 10質量部とポリェチレ ングリコール (PEG400、ライオン (株)製) 90質量部とを、 90分間 90°Cで練合した後 、シート状に展延した。  Hydroxypropylcellulose (HPC-H, Nippon Soda Co., Ltd.) 10 parts by mass and polyethylene glycol (PEG400, Lion Co., Ltd.) 90 parts by mass were kneaded at 90 ° C for 90 minutes, then in sheet form Spread out.
[0061] 実施例 1A〜14A、比較例 1A〜4Aの評価結果を表 1に示す。 [0061] Table 1 shows the evaluation results of Examples 1A to 14A and Comparative Examples 1A to 4A.
[0062] [表 1] [0062] [Table 1]
1 1
Figure imgf000023_0001
Figure imgf000023_0001
[0063] 表 1の結果から明らかなように、実施例 1A〜14Aでは、粘着性も高ぐかつ優れた ゲル形成能を有したゲル組成物であった。また、作製した貼付剤を 10cm X 14cmに 裁断して、皮膚刺激性を評価した。評価方法は、健常なパネラー 5名の前腕部内側 に貼り付け、 7時間後剥離、 1時間後再び貼付する、という工程を繰り返し行い、 5回 目の剥離後、 1時間経過時の皮膚状態を観察した。評点を 3点:貼付前と変化はない 、 2点:少し赤みを帯びている、 1点:非常に赤みを帯びているとし、各パネラーの平 均点を求めた。その結果、実施例 1A〜14Aでは、平均点が 2. 5点以上であり、痛み もなく、皮膚刺激性が低いゲル組成物であり、かつ貼付 7時間後も粘着性の低下は 見られなかった。 [0063] As is apparent from the results in Table 1, Examples 1A to 14A were gel compositions having high tackiness and excellent gel-forming ability. The prepared patch was cut into 10 cm × 14 cm to evaluate skin irritation. The evaluation method was repeated on the inside of the forearm of five healthy panelists, and after 7 hours, and after 1 hour, the skin condition after 1 hour had passed. Observed. The score was 3 points: no change from before application, 2 points: a little reddish, 1 point: very reddish, and the average score of each panel was calculated. As a result, in Examples 1A to 14A, the average score is 2.5 points or more, there is no pain, the gel composition has low skin irritation, and no decrease in adhesiveness is observed after 7 hours of application. It was.
比較例 1A〜4Aでは、高!、粘着性と優れたゲル形成能を両立することができなか つた o  Comparative Examples 1A to 4A are expensive! Inability to achieve both cohesion and excellent gel-forming ability o
(実施例 15 A)  (Example 15 A)
下記の組成を 90分間 90°Cで練合した後、シート状に展延した。  The following composition was kneaded at 90 ° C for 90 minutes, and then spread into a sheet.
[0064] [表 2] 3391 表 2 [0064] [Table 2] 3391 Table 2
Figure imgf000024_0001
Figure imgf000024_0001
[0065] 実施例 15Aでは、皮膚刺激を殆ど起こさず、高い粘着性と、かつ優れたゲル形成 能を有する貼付剤であった。 [0065] In Example 15A, the patch had little skin irritation, high adhesiveness, and excellent gel-forming ability.
(実施例 16 A)  (Example 16 A)
下記の組成を 90分間 90°Cで練合した後、シート状に展延した。  The following composition was kneaded at 90 ° C for 90 minutes, and then spread into a sheet.
[0066] [表 3] [0066] [Table 3]
3  Three
Figure imgf000024_0002
Figure imgf000024_0002
[0067] 実施例 16Aでは、皮膚刺激を殆ど起こさず、高い粘着性と、かつ優れたゲル形成 能を有する貼付剤であった。 [0067] In Example 16A, the patch had little skin irritation, high adhesiveness, and excellent gel-forming ability.
[0068] (実施例 1B〜: L0B) また、多価アルコールに薬効成分を溶解した後、経皮吸収向上剤を混合し、結合 剤、を分散混合してゲル組成物を得た。ポリウレタンフィルム Zニット積層支持体への 塗工量が 0. 7 (g/70cm2)となるように、該支持体上に外用剤組成物を塗布した。加 熱処理し、次いで、縦 X横の長さ 7cm X 10cmの大きさに裁断して、貼付剤を得た。 実施例 1B〜: LOBで用いた成分は以下のとおりである。 [0068] (Example 1B-: L0B) Further, after dissolving a medicinal component in polyhydric alcohol, a transdermal absorption enhancer was mixed, and a binder was dispersed and mixed to obtain a gel composition. The external preparation composition was applied onto the support so that the coating amount on the polyurethane film Z-knit laminated support was 0.7 (g / 70 cm 2 ). After heat treatment, the patch was cut into a size of 7 cm x 10 cm in length x width. Example 1B ~: The components used in LOB are as follows.
(A)成分  (A) component
メチルビ-ルエーテル Z無水マレイン酸力 構成される共重合体 (ISP社製、 GAN TREZ AN— 139) 100質量咅 こ、 8質量咅の水を添カロし、 90°C【こお!ヽて 180分 加水分解させることにより、 (A)ポリマーとして、無水マレイン酸 Zマレイン酸のモル 比が 56Z44のメチルビ-ルエーテル Z無水マレイン酸 Zマレイン酸から構成される 共重合体 (重量平均分子量 108万)を得た。  Methyl vinyl ether Z Maleic anhydride Copolymer (ISP, GAN TREZ AN—139) 100 mass%, 8 mass% of water added, 90 ° C [Koo! (A) As a polymer, a copolymer (weight average molecular weight 1,080,000) composed of methyl vinyl ether Z maleic anhydride Z maleic acid having a molar ratio of maleic anhydride Z maleic acid of 56Z44 was obtained. Obtained.
(B)成分  (B) component
PEG300:ポリエチレングリコール(重量平均分子量 300、ライオン (株)製) PEG400:ポリエチレングリコール(重量平均分子量 400、ライオン (株)製) PG:プロピレングリコール(商品名「プロピレングリコール PGjp」、ァヅマ(株)社製) EG :エチレングリコール (商品名「エチレングリコール (試薬)」、和光純薬工業 (株) 社製)  PEG300: Polyethylene glycol (weight average molecular weight 300, manufactured by Lion Corp.) PEG400: Polyethylene glycol (weight average molecular weight 400, manufactured by Lion Corp.) PG: Propylene glycol (trade name "Propylene glycol PGjp", Arma Co., Ltd. EG: Ethylene glycol (trade name "Ethylene glycol (reagent)", Wako Pure Chemical Industries, Ltd.)
[結合剤]  [Binder]
ヒドロキシプロピルセルロース(重量平均分子量 100万、商品名「HPC— H」、 日本 曹達 (株)社製)  Hydroxypropylcellulose (weight average molecular weight 1 million, trade name “HPC—H”, manufactured by Nippon Soda Co., Ltd.)
[経皮吸収向上剤]  [Transdermal absorption enhancer]
セバシン酸ジェチル:商品名「DES— SP」、日光ケミカルズ (株)社製  Jetyl sebacate: trade name “DES—SP”, manufactured by Nikko Chemicals Co., Ltd.
アジピン酸ジイソプロピル:商品名「DID」、 日光ケミカルズ (株)社製  Diisopropyl adipate: trade name “DID”, manufactured by Nikko Chemicals Co., Ltd.
ミリスチン酸イソプロピル:商品名「IPM— EX」、日光ケミカルズ (株)社製 ォレイン酸ォレイル:商品名「KOKOO」、高級アルコール工業 (株)社製 実施例 1B〜: L0Bで得られたゲル組成物又は貼付剤を用いて、以下の方法に従い Isopropyl myristate: trade name “IPM—EX”, manufactured by Nikko Chemicals Co., Ltd. Ololeic acid: trade name “KOKOO”, manufactured by Higher Alcohol Industry Co., Ltd. Example 1B: Gel composition obtained from L0B Or use the patch and follow the method below
、ゲル組成物中薬効成分の皮膚透過試験、貼付剤の粘着性評価を行った。結果を 表 4に示す。 <皮膚透過試験 > Then, a skin permeation test of medicinal components in the gel composition and an adhesive evaluation of the patch were performed. The results are shown in Table 4. <Skin penetration test>
Hos: HR- 1雌性へアレスマウス(7週齢)の背部から採取した皮膚を、 37°Cのリン 酸バッファ (PH7. 4等張緩衝液)を循環させたフランツ型拡散セル (適用面積 4. 91c m )に装着した。  Hos: Franz diffusion cell (applicable area: 4) 91cm).
該装着した皮膚上に、貼付剤 (実施例 1B等)を積層し単位時間毎にセル内の試料 を採取した。  A patch (Example 1B etc.) was laminated on the worn skin, and a sample in the cell was taken every unit time.
採取した試料は、高速液体クロマトグラフィー分析に供し、 2時間後の皮膚を透過し た各薬効成分の量 (薬効成分皮膚透過量、 μ g/cm2)を求めた。 The collected samples were subjected to high performance liquid chromatography analysis, and the amount of each medicinal component that permeated through the skin after 2 hours (medicinal component skin permeation amount, μg / cm 2 ) was determined.
なお、「2時間後」の薬効成分皮膚透過量が多いことは、初期の経皮吸収性に優れ ることを  A large amount of medicinal component skin permeation after 2 hours means that the initial percutaneous absorption is excellent.
表す。本評価系では、 2時間後の薬効成分皮膚透過量が 0. 5 /z gZcm2以上であれ ば初期 To express. In this evaluation system, if the medicinal component skin permeation amount after 2 hours is 0.5 / z gZcm 2 or more, the initial
の経皮吸収性に優れる。 Excellent percutaneous absorption.
<粘着性評価 > <Adhesion evaluation>
実施例 1B〜: L0Bで製造した貼付剤の粘着性を、 JIS Z— 0237試験に準じ、傾斜 角 30° で測定したときのボールタック値により評価した。  Example 1B: The adhesiveness of the patch prepared with L0B was evaluated based on the ball tack value when measured at an inclination angle of 30 ° according to the JIS Z-0237 test.
[表 4] [Table 4]
JP2006/303391 JP2006 / 303391
表 4 Table 4
実翻  Real life
IB 2B 3B 4B 5B IB 2B 3B 4B 5B
(A) 成分 15 15 15 15 15(A) Component 15 15 15 15 15
(B) 成分 (B) Component
PEG300 5 10 40 5 5 PEG300 5 10 40 5 5
PEG400 5 10 13 5 SPEG400 5 10 13 5 S
PG 40 13 40 40PG 40 13 40 40
EG 13 10 13 13 結合剤 EG 13 10 13 13 Binder
ヒ ドロキシプロピルセルロース 10 10 10 10 10 菜物  Hydroxypropylcellulose 10 10 10 10 10 Vegetables
ィンドメタシン 2 2 2 2 2 経皮吸収向上剤  Lindamecin 2 2 2 2 2 Transdermal absorption enhancer
セバシン酸ジェチノレ 10 30 20  Jetinore sebacate 10 30 20
アジピン酸ジイソプロピノレ 10 ミリスチン酸ィソプロピル 10 Diisopropinole adipate 10 Isopropyl myristate 10
2時間後の薬効成分皮麼透過量 ( g/cm2) 1. 6 1. 7 1. 4 1. 6 1. 0 粘着性 ◎ ◎ © ◎ ◎ 表 4 (続き) Permeable skin permeation after 2 hours (g / cm 2 ) 1. 6 1. 7 1. 4 1. 6 1. 0 Adhesiveness ◎ ◎ © ◎ ◎ Table 4 (Continued)
実施例  Example
6B 7B 8B 9B 10B 6B 7B 8B 9B 10B
(A) 成分 15 15 15 15 15(A) Component 15 15 15 15 15
(B) 成分 (B) Component
PEG300 5 5 5 10 PEG300 5 5 5 10
PEG棚 5 5 10 5 10PEG shelf 5 5 10 5 10
PG 40 40 40 PG 40 40 40
EG 13 13 40 53 ジプロピレングリコーノレ 13 13 結合剤  EG 13 13 40 53 Dipropylene glycolate 13 13 Binder
ヒ ドロキシプロピノレセノレロース 10 10 10 10 10 薬物  Hydroxypropinoresenorelose 10 10 10 10 10 Drug
インドメタシン 2 2 2 2 フェルビナク 2  Indomethacin 2 2 2 2 Felbinac 2
径皮吸収向上剤 Diameter absorption enhancer
セノ ίシン酸ジェチノレ 10 10 10 アジピン酸ジイソプロピノレ 10  Seno ί Jetinore cinnamate 10 10 10 Diisopropinole adipate 10
ォレイン酸ォレイル 10  Oleate oleate 10
2時閉後の薬効成分皮 透過量 ( n g/cm2) 1. 2 2. 4 1. 2 1. 3 1. 8 粘着性 ◎ © ◎ ◎ ◎ Permeation rate of medicinal component after 2 o'clock closing (ng / cm 2 ) 1. 2 2. 4 1. 2 1. 3 1. 8 Adhesiveness ◎ © ◎ ◎ ◎

Claims

請求の範囲 The scope of the claims
[1] (A)少なくとも 1つの不飽和部分と酸無水物部分とから構成される繰り返し単位と、 少なくとも 1つの不飽和部分と該酸無水物部分に対応する酸化合物部分とから構成 される繰り返し単位とを含むポリマーと、 (B)多価アルコールとを含有するゲル組成物 であって、  [1] (A) a repeating unit composed of at least one unsaturated moiety and an acid anhydride moiety, and at least one unsaturated moiety and an acid compound moiety corresponding to the acid anhydride moiety A gel composition comprising a polymer containing units and (B) a polyhydric alcohol,
(A)ポリマーが、酸無水物部分と該酸無水物部分に対応する酸化合物部分とを、 モル比にして 15Z85〜85Z 15なる割合で含むことを特徴とする前記ゲル組成物。  (A) The gel composition, wherein the polymer contains an acid anhydride part and an acid compound part corresponding to the acid anhydride part in a molar ratio of 15Z85 to 85Z15.
[2] (A)少なくとも 1つの不飽和部分がビニルイ匕合物であり、酸無水物部分が無水マレ イン酸部分、無水ィタコン酸部分力 なる群力 選ばれる請求項 1記載のゲル組成物 [2] The gel composition according to claim 1, wherein (A) at least one unsaturated portion is a vinyl compound, and the acid anhydride portion is selected from the group strength of maleic anhydride portion and itaconic anhydride partial force.
[3] (A)ポリマー力 炭素数 3〜24のアルキルビュルエーテル Z無水マレイン酸 Zマレ イン酸から構成される共重合体、炭素数 3〜24のアルキルビニルエーテル Z無水ィ タコン酸 Zイタコン酸から構成される共重合体からなる群から選ばれる請求項 2記載 のゲル組成物。 [3] (A) Polymer strength C3-C24 alkyl butyl ether Z Maleic anhydride Copolymer composed of maleic acid, C3-C24 alkyl vinyl ether Z Itaconic anhydride Z Itaconic acid The gel composition according to claim 2, wherein the gel composition is selected from the group consisting of copolymers.
[4] 炭素数 3〜24のアルキルビュルエーテル Z無水マレイン酸 Zマレイン酸から構成 される共重合体力 メチルビ-ルエーテル Z無水マレイン酸 Zマレイン酸力 構成さ れる共重合体である、請求項 3記載のゲル組成物。  [4] The copolymer power composed of alkyl butyl ether having 3 to 24 carbon atoms, Z maleic anhydride, and maleic acid. 4. The copolymer is composed of methyl vinyl ether, Z maleic anhydride, and maleic power. Gel composition.
[5] (A)ポリマーにおける酸無水物部分と該酸無水物部分に対応する酸ィ匕合物部分と のモル比力 20Z80〜70Z30である請求項 1〜4の!、ずれか 1項記載のゲル組成 物。 [5] (A) The molar specific power of the acid anhydride part in the polymer and the acid compound part corresponding to the acid anhydride part is 20Z80 to 70Z30! Gel composition.
[6] (B)多価アルコールが、 1, 3—ブチレングリコール、エチレングリコール、プロピレン グリコール、グリセリン、ジグリセリン、トリグリセリン、ポリグリセリン、ジエチレングリコー ル、ジプロピレングリコール、トリエチレングリコール、ポリエチレングリコール、ポリプロ ピレンダリコール、ポリエチレン ·ポリプロピレングリコール、ポリオキシエチレン硬化ヒ マシ油およびソルビトールカ なる群力 選ばれる請求項 1〜5のいずれか 1項記載 のゲル組成物。  [6] (B) The polyhydric alcohol is 1,3-butylene glycol, ethylene glycol, propylene glycol, glycerin, diglycerin, triglycerin, polyglycerin, diethylene glycol, dipropylene glycol, triethylene glycol, polyethylene glycol, The gel composition according to any one of claims 1 to 5, which is selected from the group consisting of polypropylene glycol, polyethylene / polypropylene glycol, polyoxyethylene hydrogenated castor oil and sorbitol.
[7] (B)多価アルコール力 重量平均分子量 200〜2000のポリエチレングリコールを 含有する 2〜6価の多価アルコール混合物である請求項 1〜5のいずれ力 1項記載の ゲル組成物。 [7] (B) Polyhydric alcohol power The power according to any one of claims 1 to 5, wherein the polyhydric alcohol mixture is a dihydric to hexahydric alcohol mixture containing polyethylene glycol having a weight average molecular weight of 200 to 2000. Gel composition.
[8] (A)ポリマーと(B)多価アルコールと力 質量比にして、 1Z99〜55Z45なる割合 で含まれて 、る請求項 1〜7の 、ずれか 1項記載のゲル組成物。  [8] The gel composition according to any one of claims 1 to 7, wherein (A) the polymer and (B) the polyhydric alcohol are contained in a mass ratio of 1Z99 to 55Z45.
[9] 更に、結合剤を含有する請求項 1〜8のいずれか 1項記載のゲル組成物。 [9] The gel composition according to any one of claims 1 to 8, further comprising a binder.
[10] 結合剤が、カルボキシビュルポリマー、アルギン酸、ポリビュルアルコール、ポリビ- ルピロリドン、カルボキシメチルセルロース、ヒドロキシプロピルセルロース及びヒドロキ シプロピルメチルセルロース力 なる群力 選ばれる少なくとも 1種である請求項 9記 載のゲル組成物。 [10] The binder according to claim 9, wherein the binder is at least one selected from the group force of carboxybule polymer, alginic acid, polybulal alcohol, polyvinylpyrrolidone, carboxymethylcellulose, hydroxypropylcellulose and hydroxypropylmethylcellulose. Gel composition.
[11] 更に、薬効成分を含有する請求項 1〜10のいずれか 1項記載のゲル組成物。  [11] The gel composition according to any one of claims 1 to 10, further comprising a medicinal component.
[12] 更に、下記式(1) :  [12] Further, the following formula (1):
(R2OOC) - R1 - R3 (1) (R 2 OOC)-R 1 -R 3 (1)
[式中、 R1は炭素数 3〜36の炭化水素基であり、 R2は炭素数 1〜20の炭化水素基で あり、 R3は水素原子又は— COOR4 (R4は炭素数 1〜: LOの炭化水素基である)である o ] [Wherein R 1 is a hydrocarbon group having 3 to 36 carbon atoms, R 2 is a hydrocarbon group having 1 to 20 carbon atoms, R 3 is a hydrogen atom or —COOR 4 (R 4 is 1 carbon atom ~: Is a hydrocarbon group of LO) o]
で表される経皮吸収向上剤を含有する請求項 1〜11のいずれか 1項記載のゲル組 成物。  The gel composition according to any one of claims 1 to 11, comprising a transdermal absorption enhancer represented by the formula:
[13] 前記エステル力 セバシン酸ジェチル、セバシン酸ジイソプロピル、アジピン酸ジェ チル、アジピン酸ジイソプロピル、ォレイン酸ォレイル、ミリスチン酸イソプロピル、パル ミチン酸イソプロピル、リノール酸ェチル及びリノール酸イソプロピルからなる群からな る群力も選ばれる少なくとも 1種である請求項 12記載のゲル組成物。  [13] The ester power group consisting of cetyl sebacate, diisopropyl sebacate, dimethyl adipate, diisopropyl adipate, oleyl oleate, isopropyl myristate, isopropyl palmitate, ethyl linoleate and isopropyl linoleate 13. The gel composition according to claim 12, wherein the gel composition is at least one selected from force.
[14] 架橋剤を含有しな ヽ、請求項 1〜13の 、ずれか 1項記載のゲル組成物。 [14] The gel composition according to any one of claims 1 to 13, which does not contain a crosslinking agent.
[15] 支持体上に請求項 1〜14のいずれ力 1項記載のゲル組成物が展延されてなる貼 付剤。 [15] An adhesive agent obtained by spreading the gel composition according to any one of claims 1 to 14 on a support.
[16] (a)少なくとも 1つの不飽和部分と酸無水物部分とから構成される繰り返し単位を含 むポリマーを加水分解して、ポリマー中に含まれる酸無水物部分と該酸無水物部分 に対応する酸化合物部分とが、モル比にして 15Z85〜85Z15である、(A)少なくと も 1つの不飽和部分と酸無水物部分とから構成される繰り返し単位と、少なくとも 1つ の不飽和部分と該酸無水物部分に対応する酸化合物部分とから構成される繰り返し 単位とを含むポリマーを得る工程、 [16] (a) A polymer containing a repeating unit composed of at least one unsaturated moiety and an acid anhydride moiety is hydrolyzed to form an acid anhydride moiety and an acid anhydride moiety contained in the polymer. The corresponding acid compound part is in a molar ratio of 15Z85 to 85Z15 (A) a repeating unit composed of at least one unsaturated part and an acid anhydride part, and at least one unsaturated part And an acid compound portion corresponding to the acid anhydride portion. Obtaining a polymer comprising units,
得られた (A)ポリマーを、(B)多価アルコールに溶解させる工程、及び 架橋剤の不存在下、得られた混合物を加熱する工程、  A step of dissolving the obtained (A) polymer in (B) a polyhydric alcohol, and a step of heating the resulting mixture in the absence of a crosslinking agent;
を含む、ゲル組成物の製造方法。 A method for producing a gel composition, comprising:
PCT/JP2006/303391 2005-02-24 2006-02-24 Gel composition and method for producing same WO2006090824A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005-049347 2005-02-24
JP2005049347A JP4786196B2 (en) 2005-02-24 2005-02-24 Gel composition and method for producing the same

Publications (1)

Publication Number Publication Date
WO2006090824A1 true WO2006090824A1 (en) 2006-08-31

Family

ID=36927457

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/303391 WO2006090824A1 (en) 2005-02-24 2006-02-24 Gel composition and method for producing same

Country Status (2)

Country Link
JP (1) JP4786196B2 (en)
WO (1) WO2006090824A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015502940A (en) * 2011-11-30 2015-01-29 アシノ アーゲー Transdermal therapeutic system for administration of fentanyl or its analogs
JP2015051961A (en) * 2013-06-05 2015-03-19 国立大学法人九州大学 Percutaneous absorption substrate

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5836561B2 (en) * 2008-09-30 2015-12-24 小林製薬株式会社 Topical skin preparation
CN115970043A (en) * 2022-09-09 2023-04-18 吉林大学 Adhesive for repairing tissue and preparation method and application thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6392683A (en) * 1986-10-08 1988-04-23 Advance Co Ltd Tacky conductive gel
JPH06212045A (en) * 1992-08-13 1994-08-02 Adcock Ingram Pharmaceut Ltd Hydrogel composition and preparation thereof
JPH07503974A (en) * 1992-02-25 1995-04-27 アラーガン、インコーポレイテッド pH-sensitive reversibly gelling erodible drug delivery system
JPH09169640A (en) * 1995-10-18 1997-06-30 Sekisui Chem Co Ltd External preparation for treating dermatosis
JP2003113077A (en) * 2001-09-28 2003-04-18 Lion Corp Plaster
JP2003212760A (en) * 2002-01-17 2003-07-30 Lion Corp Gel composition and gel sheet
EP1506771A1 (en) * 2003-08-04 2005-02-16 GC Corporation Gel-like tooth whitening material composition

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6392683A (en) * 1986-10-08 1988-04-23 Advance Co Ltd Tacky conductive gel
JPH07503974A (en) * 1992-02-25 1995-04-27 アラーガン、インコーポレイテッド pH-sensitive reversibly gelling erodible drug delivery system
JPH06212045A (en) * 1992-08-13 1994-08-02 Adcock Ingram Pharmaceut Ltd Hydrogel composition and preparation thereof
JPH09169640A (en) * 1995-10-18 1997-06-30 Sekisui Chem Co Ltd External preparation for treating dermatosis
JP2003113077A (en) * 2001-09-28 2003-04-18 Lion Corp Plaster
JP2003212760A (en) * 2002-01-17 2003-07-30 Lion Corp Gel composition and gel sheet
EP1506771A1 (en) * 2003-08-04 2005-02-16 GC Corporation Gel-like tooth whitening material composition

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015502940A (en) * 2011-11-30 2015-01-29 アシノ アーゲー Transdermal therapeutic system for administration of fentanyl or its analogs
JP2015051961A (en) * 2013-06-05 2015-03-19 国立大学法人九州大学 Percutaneous absorption substrate

Also Published As

Publication number Publication date
JP4786196B2 (en) 2011-10-05
JP2006232724A (en) 2006-09-07

Similar Documents

Publication Publication Date Title
JP4398158B2 (en) Patch
JP5650684B2 (en) Water-containing external patch composition and patch using this composition
BR0109198B1 (en) Plaster having a backing
JP4920206B2 (en) External preparation composition and patch, and percutaneous absorption composition of drug
CN104379139A (en) Skin patch
JP4596751B2 (en) Anti-inflammatory analgesic patch
JP3739100B2 (en) Low temperature crosslinking gel
JP5089933B2 (en) Water-containing pressure-sensitive adhesive composition and patch using the same
JP2002020274A (en) Non-steroidal anti-inflammatory analgesic transdermal patch agent for outer application and transdermal patch for outer application
JP4430120B2 (en) Antimycotic patch
EP3266451A1 (en) Adhesive plaster
WO2006090824A1 (en) Gel composition and method for producing same
JPS61275212A (en) Ketoprofen-containing poultice
JP5175041B2 (en) Hydrophilic adhesive, hydrophilic external skin adhesive composition and hydrophilic patch using the same
JPH04217919A (en) Percutaneously eperisone or tolperisone-absorbing preparation
JPH08243377A (en) Alcohol-containing gel body
JP3276188B2 (en) Patch and method for producing the same
JP3144895B2 (en) Medical adhesive tape or sheet
WO2006093066A1 (en) Pressure-sensitive adhesive base and medical adhesive patch including the pressure-sensitive adhesive base
JP3193161B2 (en) Transdermal absorption preparation
JPH09268123A (en) Cataplasm for local anesthesia
JPH0413617A (en) Patch
JP2887548B2 (en) Hydrous skin external patch with improved usability
JPH078784B2 (en) Hydrophilic transdermal preparation
JP4567998B2 (en) Hydrophilic external skin pressure-sensitive adhesive composition and hydrophilic patch using hydrophilic pressure-sensitive adhesive

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06714530

Country of ref document: EP

Kind code of ref document: A1